ZA200410292B - Utilization of heteroarene carboxamide as dopamine-D3 ligands for the treatment of CNS diseases. - Google Patents
Utilization of heteroarene carboxamide as dopamine-D3 ligands for the treatment of CNS diseases. Download PDFInfo
- Publication number
- ZA200410292B ZA200410292B ZA200410292A ZA200410292A ZA200410292B ZA 200410292 B ZA200410292 B ZA 200410292B ZA 200410292 A ZA200410292 A ZA 200410292A ZA 200410292 A ZA200410292 A ZA 200410292A ZA 200410292 B ZA200410292 B ZA 200410292B
- Authority
- ZA
- South Africa
- Prior art keywords
- alkyl
- halogen
- cyano
- hydrogen
- alkinyl
- Prior art date
Links
- -1 heteroarene carboxamide Chemical class 0.000 title claims description 22
- 239000003446 ligand Substances 0.000 title description 15
- 208000015114 central nervous system disease Diseases 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 79
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 76
- 150000002367 halogens Chemical class 0.000 claims description 65
- 229910052736 halogen Inorganic materials 0.000 claims description 64
- 229910052739 hydrogen Inorganic materials 0.000 claims description 60
- 239000001257 hydrogen Substances 0.000 claims description 59
- 125000000217 alkyl group Chemical group 0.000 claims description 52
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 48
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 44
- 150000002431 hydrogen Chemical group 0.000 claims description 43
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 39
- 125000003342 alkenyl group Chemical group 0.000 claims description 38
- 125000006193 alkinyl group Chemical group 0.000 claims description 38
- 125000003118 aryl group Chemical group 0.000 claims description 38
- 125000003545 alkoxy group Chemical group 0.000 claims description 36
- 125000002252 acyl group Chemical group 0.000 claims description 34
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 34
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 62
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 30
- 102000005962 receptors Human genes 0.000 description 23
- 108020003175 receptors Proteins 0.000 description 23
- 230000015572 biosynthetic process Effects 0.000 description 22
- 238000003786 synthesis reaction Methods 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 239000003814 drug Substances 0.000 description 20
- 238000005160 1H NMR spectroscopy Methods 0.000 description 18
- 238000005481 NMR spectroscopy Methods 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- 208000035475 disorder Diseases 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 14
- 125000001424 substituent group Chemical group 0.000 description 14
- 229910052801 chlorine Inorganic materials 0.000 description 13
- 239000000460 chlorine Substances 0.000 description 13
- 229940124597 therapeutic agent Drugs 0.000 description 13
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 12
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 12
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 12
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 12
- 229910052794 bromium Inorganic materials 0.000 description 12
- 229910052731 fluorine Inorganic materials 0.000 description 12
- 239000011737 fluorine Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 208000010118 dystonia Diseases 0.000 description 11
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 10
- 208000012661 Dyskinesia Diseases 0.000 description 10
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000002287 radioligand Substances 0.000 description 10
- 108050004812 Dopamine receptor Proteins 0.000 description 9
- 102000015554 Dopamine receptor Human genes 0.000 description 9
- 208000018737 Parkinson disease Diseases 0.000 description 9
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 9
- 230000033001 locomotion Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 7
- 229960003638 dopamine Drugs 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 208000014094 Dystonic disease Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 206010013663 drug dependence Diseases 0.000 description 5
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 5
- 229960001289 prazosin Drugs 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 4
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 4
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 4
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 4
- 206010008531 Chills Diseases 0.000 description 4
- 208000022497 Cocaine-Related disease Diseases 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 230000001270 agonistic effect Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 201000006145 cocaine dependence Diseases 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 239000003176 neuroleptic agent Substances 0.000 description 4
- 230000000701 neuroleptic effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 201000000980 schizophrenia Diseases 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 239000008096 xylene Substances 0.000 description 4
- 101710155073 2-amino-3,7-dideoxy-D-threo-hept-6-ulosonate synthase Proteins 0.000 description 3
- ZLBICQIZTNCOCN-UHFFFAOYSA-N 4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butan-1-amine Chemical compound C1CN(CCCCN)CCN1C1=CC=CC(Cl)=C1Cl ZLBICQIZTNCOCN-UHFFFAOYSA-N 0.000 description 3
- UFJPFLDFMPVGRW-UHFFFAOYSA-N 4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-amine Chemical compound COC1=CC=CC=C1N1CCN(CCCCN)CC1 UFJPFLDFMPVGRW-UHFFFAOYSA-N 0.000 description 3
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 3
- 108091005479 5-HT2 receptors Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108060003345 Adrenergic Receptor Proteins 0.000 description 3
- 102000017910 Adrenergic receptor Human genes 0.000 description 3
- 206010001540 Akathisia Diseases 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 206010057852 Nicotine dependence Diseases 0.000 description 3
- 208000026251 Opioid-Related disease Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 208000005793 Restless legs syndrome Diseases 0.000 description 3
- 201000001880 Sexual dysfunction Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 208000025569 Tobacco Use disease Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960003920 cocaine Drugs 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 208000016570 early-onset generalized limb-onset dystonia Diseases 0.000 description 3
- 150000002390 heteroarenes Chemical class 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 208000031424 hyperprolactinemia Diseases 0.000 description 3
- 229960004502 levodopa Drugs 0.000 description 3
- 208000024714 major depressive disease Diseases 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229940127240 opiate Drugs 0.000 description 3
- 201000005040 opiate dependence Diseases 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 231100000872 sexual dysfunction Toxicity 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 2
- UDQMXYJSNNCRAS-UHFFFAOYSA-N 2,3-dichlorophenylpiperazine Chemical class ClC1=CC=CC(N2CCNCC2)=C1Cl UDQMXYJSNNCRAS-UHFFFAOYSA-N 0.000 description 2
- SGVBRIHFEULKBC-UHFFFAOYSA-N 2-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]isoindole-1,3-dione Chemical compound ClC1=CC=CC(N2CCN(CCCCN3C(C4=CC=CC=C4C3=O)=O)CC2)=C1Cl SGVBRIHFEULKBC-UHFFFAOYSA-N 0.000 description 2
- GDRNNGAOPZOKFM-UHFFFAOYSA-N 4-(4-bromobutyl)isoindole-1,3-dione Chemical compound BrCCCCC1=CC=CC2=C1C(=O)NC2=O GDRNNGAOPZOKFM-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 2
- 229960005417 ketanserin Drugs 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000008054 signal transmission Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- IAJILQKETJEXLJ-KKQCNMDGSA-N (2r,3r,4r,5s)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid Chemical compound O=C[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O IAJILQKETJEXLJ-KKQCNMDGSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- GOTMKOSCLKVOGG-OAHLLOKOSA-N (5R)-8-chloro-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol Chemical compound C1([C@@H]2C3=CC(O)=C(Cl)C=C3CCN(C2)C)=CC=CC=C1 GOTMKOSCLKVOGG-OAHLLOKOSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UWTATZPHSA-N (R)-malic acid Chemical compound OC(=O)[C@H](O)CC(O)=O BJEPYKJPYRNKOW-UWTATZPHSA-N 0.000 description 1
- CEGRHPCDLKAHJD-UHFFFAOYSA-N 1,1,1-propanetricarboxylic acid Chemical compound CCC(C(O)=O)(C(O)=O)C(O)=O CEGRHPCDLKAHJD-UHFFFAOYSA-N 0.000 description 1
- DYSJMQABFPKAQM-UHFFFAOYSA-N 1-benzothiophene-2-carboxylic acid Chemical compound C1=CC=C2SC(C(=O)O)=CC2=C1 DYSJMQABFPKAQM-UHFFFAOYSA-N 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- FITNPEDFWSPOMU-UHFFFAOYSA-N 2,3-dihydrotriazolo[4,5-b]pyridin-5-one Chemical compound OC1=CC=C2NN=NC2=N1 FITNPEDFWSPOMU-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- NYHNVHGFPZAZGA-UHFFFAOYSA-N 2-hydroxyhexanoic acid Chemical compound CCCCC(O)C(O)=O NYHNVHGFPZAZGA-UHFFFAOYSA-N 0.000 description 1
- JRHWHSJDIILJAT-UHFFFAOYSA-N 2-hydroxypentanoic acid Chemical compound CCCC(O)C(O)=O JRHWHSJDIILJAT-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- FGSBNBBHOZHUBO-UHFFFAOYSA-N 2-oxoadipic acid Chemical compound OC(=O)CCCC(=O)C(O)=O FGSBNBBHOZHUBO-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- QKUWZCOVKRUXKX-UHFFFAOYSA-N 5-bromo-1-benzofuran-2-carboxylic acid Chemical compound BrC1=CC=C2OC(C(=O)O)=CC2=C1 QKUWZCOVKRUXKX-UHFFFAOYSA-N 0.000 description 1
- UJQXZANNFIHPGV-UHFFFAOYSA-N 5-cyano-1-benzofuran-2-carboxylic acid Chemical compound N#CC1=CC=C2OC(C(=O)O)=CC2=C1 UJQXZANNFIHPGV-UHFFFAOYSA-N 0.000 description 1
- ZYPDMDQLHAAUOJ-UHFFFAOYSA-N 5-cyano-1-benzothiophene-2-carboxylic acid Chemical compound N#CC1=CC=C2SC(C(=O)O)=CC2=C1 ZYPDMDQLHAAUOJ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- AEMOLEFTQBMNLQ-DTEWXJGMSA-N D-Galacturonic acid Natural products O[C@@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-DTEWXJGMSA-N 0.000 description 1
- ODBLHEXUDAPZAU-ZAFYKAAXSA-N D-threo-isocitric acid Chemical compound OC(=O)[C@H](O)[C@@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-ZAFYKAAXSA-N 0.000 description 1
- 101150049660 DRD2 gene Proteins 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000865224 Homo sapiens D(3) dopamine receptor Proteins 0.000 description 1
- 101000939500 Homo sapiens UBX domain-containing protein 11 Proteins 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- ODBLHEXUDAPZAU-FONMRSAGSA-N Isocitric acid Natural products OC(=O)[C@@H](O)[C@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-FONMRSAGSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 102100029645 UBX domain-containing protein 11 Human genes 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 1
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 229940054066 benzamide antipsychotics Drugs 0.000 description 1
- 150000003936 benzamides Chemical class 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 229960001270 d- tartaric acid Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 208000009985 drug-induced dyskinesia Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000010491 emotional process Effects 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 238000006698 hydrazinolysis reaction Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940116298 l- malic acid Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- DPVFGTCJQOIENR-UHFFFAOYSA-N n-phenyl-n-piperazin-1-ylnaphthalene-1-carboxamide Chemical compound C=1C=CC2=CC=CC=C2C=1C(=O)N(C=1C=CC=CC=1)N1CCNCC1 DPVFGTCJQOIENR-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- FTSUPYGMFAPCFZ-ZWNOBZJWSA-N quinpirole Chemical compound C([C@H]1CCCN([C@@H]1C1)CCC)C2=C1C=NN2 FTSUPYGMFAPCFZ-ZWNOBZJWSA-N 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229910052714 tellurium Inorganic materials 0.000 description 1
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- ODBLHEXUDAPZAU-UHFFFAOYSA-N threo-D-isocitric acid Natural products OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D345/00—Heterocyclic compounds containing rings having selenium or tellurium atoms as the only ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F17/00—Metallocenes
- C07F17/02—Metallocenes of metals of Groups 8, 9 or 10 of the Periodic System
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
~ SE
W0O/2004/004729 PCT/EP2003/007060
Utilization of Heteroarene Carboxamide as Dopamine-D3 Ligands for the Treatment of CNS Diseases
Dopamine is considered an important neurotransmitter of the central nervous system. Dopamine acts by binding to five different dopamine receptors. Owing to their morphology and the manner of signal transmission, these may be classified as Dl-like (D1 and DS) and D2-like (D2, D3 and D4) receptors (Neve, K.A. The Dopamine Receptors. Humana Press, 1997). Especially the subtypes of the D2 family play an important role in regulatory processes of the central nervous system. While the D2 receptors are primarily expressed in the basal ganglia where they control neuromotoric circuits, D3 receptors are mainly found in the limbic system where emotional and cognitive processes are controlled. Disorders in the signal transduction of these receptors result in numerous neuropathological situations. Especially the D3 receptor is considered a promising target for the development of active ingredients to treat psychiatric diseases such as schizophrenia or unipolar depression, disturbances of consciousness as well as for the treatment of neurodegenerative diseases such as Parkinson's disease, but also for the treatment of drug addiction (Pulvirenti, L. et al. Trends Pharmacol. Sci. 2002, 23, 151-153).
Compounds having an aryl piperazine structure have already been described as ’ dopamine receptor-active ligands (Robarge, M.J. J. Med. Chem. 2001, 44, - 3175-3186). Benzamides and naphthamides having an aryl piperazine partial structure are also known as ligands of dopamine receptors (Perrone, R. J. Med.
Chem. 1998, 41, 4903-4909; EP 0 779 284 Al). A phenyl piperazinyl naphthamide has recently been described as a selective D3-partial agonist showing promising activity in animal models which might be used for the treatment of cocaine addiction (Pilla, M. et al. Nature 1999, 400, 371-375).
For a few examples, aryl piperazinyl amides having oxygen-, sulfur- or nitrogen-containing heteroarenic acid components have been described (ES 2 027 898; EP 0343 961; US 3,646,047; US 3,734,915). Cyano-substituted and
2 | 2 PCT/EP2003/007060 tellurium-containing derivatives with a ferrocenyl partial structure, on the other hand, are not known in literature.
In the course of our experiments concerning the effects of the structure of dopamine ligands we have discovered new compounds of the formulae (I) to (IV) which show hitherto unknown highly affine and highly selective binding characteristics to the D3 receptor in in vitro assays. These compounds could thus be valuable therapeutic agents for the treatment of diseases of the central i nervous system such as schizophrenia, various forms of depression, neurodegenerative disorders, sexual dysfunction as well as cocaine, opiate and nicotine addiction.
Other specific areas of application are glaucoma, cognitive disorders, restless leg syndrome, hyperactivity syndrome (ADHS), hyperprolactinaemia, hyperprolactinoma, locomotion disorders associated with Parkinson's disease, treatment of L-DOPA- and neuroleptic-induced locomotion disorders, for example akathisia, rigor, dystonia and dyskinesias.
The subject matter of the present invention are derivatives of 2-heteroarene carboxylic acid amides having an aryl piperazinyl partial structure in the form of the free base and salts thereof as represented by the following formulae (I) and (II):
R
Ri 4 \ 0 6 5 5rY NN \ / NN —\ Ry
NN 2 ()
NG H n \/ 7 2 X 7s Ra 0) 6___5 a ~
NEY N ye an 2
ALI NEAR NY
JJ 2 3 wherein in formula (I): - n=1-4and
A] . ] 3 PCT/EP2003/007060 - R= hydrogen, alkyl! or halogen and (a X=SorO0: (1) when Rj is hydroxy, alkyloxy, alkenyl, alkinyl, aryl, acyl, alkoxycarbonyl or cyano, each of Ry and Rj3 are independently selected from hydrogen, hydroxy, alkyloxy, alkyl, alkenyl, alkinyl, aryl, halogen, trifluoromethyl, acyl, alkoxycarbonyl and cyano, (i) when Rj is hydrogen, alkyl, halogen or trifluoromethyl, : Rj is selected from hydroxy, alkenyl, alkinyl, aryl, acyl, alkoxycarbonyl and cyano and R3 is selected from hydrogen, hydroxy, alkyloxy, alkyl, alkenyl, alkinyl, aryl, halogen, trifluoromethyl, acyl, alkoxycarbonyl and cyano, or (b) X=NH:
Rj is selected from hydrogen, hydroxy, alkyl, alkyloxy, alkenyl, alkinyl, aryl, trifluoromethyl, acyl, alkoxycarbonyl, halogen and cyano and each of Rp and Rj3 are selected independently from hydrogen, hydroxy, alkyloxy, alkyl, alkenyl, alkinyl, aryl, halogen, trifluoromethyl, acyl, alkoxycarbonyl and cyano, with the proviso that the compound is not N-4-(4-(2- methoxyphenyl)piperazine-1-yl)butyl-2-indolylcarbamide, or (c) X=Te:
R is selected from hydrogen, hydroxy, alkyl, alkyloxy, alkenyl, alkinyl, aryl, halogen, trifluoromethyl, acyl, alkoxycarbonyl and : cyano and each of Rp and Rj3 are selected independently from hydrogen, hydroxy, alkyloxy, alkyl, alkenyl, alkinyl, aryl, halogen, trifluoromethyl, acyl, alkoxycarbonyl and cyano.
In one embodiment of the invention, the following applies in formula (I): - n=1-4 : and - X= Te, when R = hydrogen, alkyl or halogen and Ry is substituted by the radicals hydrogen, hydroxy, alkyl, alkyloxy, alkenyl, alkinyl, aryl, halogen, trifluoromethyl, acyl, alkoxycarbonyl or cyano and Rj and R3 are substituted individually or jointly by the radicals hydrogen,
. @ | 4 PCT/EP2003/007060 hydroxy, alkyloxy, alkyl, alkenyl, alkinyl, aryl, halogen, trifluoromethyl, acyl, alkoxycarbonyl or cyano, or _ X =S or QO, when R = hydrogen, alkyl or halogen and R is substituted by the radicals hydroxy, alkyloxy, alkenyl, alkinyl, aryl, acyl, alkoxycarbonyl or cyano and Rp and Rj are substituted individually or jointly by the radicals hydrogen, hydroxy, alkyloxy, alkyl, alkenyl, : alkinyl, aryl, halogen, trifluoromethyl, acyl, alkoxycarbonyl or cyano,
OF
_ X =S or O, when R = hydrogen, alkyl or halogen and R is substituted by the radicals hydrogen, alkyl, halogen or trifluoromethyl and R» and
R3 are substituted individually or jointly by the radicals hydroxy, alkenyl, alkinyl, aryl, acyl, alkoxycarbonyl or cyano, or _ X= NH, when R = hydrogen, alkyl or halogen and R is substituted by the radicals hydroxy, alkyl, alkyloxy, alkenyl, alkinyl, aryl, trifluoromethyl, acyl, alkoxycarbonyl or cyano, it being required that alkyl and alkyloxy contain at least two carbon atoms, and Rj and R3 are substituted individually or jointly by the radicals hydrogen, hydroxy, alkyloxy, alkyl, alkenyl, alkinyl, aryl, halogen, trifluoromethyl, acyl, alkoxycarbonyl or cyano and alkyloxy comprises at least two carbon atoms.
In formula (II), : n=1-4 and Rj and Ry individually or jointly represent the radicals hydrogen, hydroxy, alkyloxy, alkyl, alkenyl, alkinyl, aryl, halogen, trifluoromethyl, acyl, alkoxycarbonyl or cyano.
In particular, the invention relates to physiologically acceptable salts of the compounds of the invention.
A skilled practitioner will be aware that, depending on the choice of substituents, optically active compounds may result. In that case, both the racemates and each of the pure enantiomeric forms are subject matters of the present invention.
.. ® 5 PCT/EP2003/007060
The substituents listed in the description and the accompanying claims especially comprise the groups discussed below. "Alkyl" may be a branched or unbranched alkyl group which preferably contains 1 to 10 carbon atoms, especially preferably 1 to 6 carbon atoms and most preferably 1, 2 or 3 carbon atoms, e.g. methyl, ethyl, n-propyl, iso- propyl, n-butyl, iso-butyl, s-butyl, t-butyl, n-pentyl, iso-pentyl, neopentyl, t- pentyl, 1-methylbutyl, 2-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl and n-hexyl. Alkyl groups may additionally be substituted with one or more substituents, for example with halogen or one or more phenyl groups. "Alkenyl" and "alkinyl" have at least one double or triple bond. They may be branched or unbranched and preferably comprise 2 to 6 carbon atoms.
Alkenyls or alkinyls are preferably bound to the heteroarene or phenyl ring of the skeletal structure of the compound in such a manner that the double or triple bond is conjugated to the aromatic ring. Alkenyl and alkinyl may additionally be substituted with one or more substituents, preferably with phenyl; in that case the phenyl group is preferably located on the carbon atom 2 (if alkenyl or alkinyl is bound to the heteroarene or phenyl ring of the skeletal structure via the carbon atom 1). The alkenyls or alkinyls are preferably unsubstituted. “Alkyloxy" is the -O-alkyl group, wherein alkyl is preferably selected from the groups listed above for "alkyl": Preferably, alkyloxy is a C;-Cg-alkyloxy group, especially methoxy. In another embodiment, alkyloxy may also be a C,-
Cs-alkyloxy group. "Aryl" preferably is phenyl. Optionally, phenyl may also be substituted independently in one or more of the positions 2, 3 and 4, for example with alkoxy, trifluoromethyl or halogen, preferably with methoxy. "Acyl" especially comprises the groups -C(O)-alkyl and -C(O)-aryl, wherein alkyl and aryl are preferably selected from the groups given for "alkyl" and "aryl" above, especially -C(0O)-C;-Cg-alkyl. For example, acyl is may be acetyl, propionyl, butyryl or -C(O)-phenyl.
. @ | 6 PCT/EP2003/007060 "Alkoxycarbonyl" is the -C(O)-O-alkyl group, wherein alkyl is preferably selected from the groups listed for "alkyl" above. Preferably, alkoxycarbonyl is a (C,-Cg-alkyl)oxy carbonyl group "Halogen" is preferably fluorine, chlorine, bromine or iodine. "Physiologically acceptable salts" comprise non-toxic addition salts of a base, especially of a compound of the formula (I) in the form of the free base with organic or inorganic acids. Examples for inorganic acids include HCI, HBr, sulfuric acid and phosphoric acid. Organic acids include acetic acid, propionic acid, pyruvic acid, butyric acid, a-, B- or y-hydroxybutyric acid, valeric acid, hydroxyvaleric acid, capronic acid, hydroxycapronic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, glycolic acid, lactic acid, D-glucuronic acid, L-glucuronic acid, D-galacturonic acid, glycine, benzoic acid, hydroxybenzoic acid, gallic acid, salicylic acid, vanillic acid, cumaric acid, caffeic acid, hippuric acid, orotic acid, L-tartaric acid, D-tartaric acid, D,L-tartaric acid, meso-tartaric acid, fumaric acid, L-malic acid, D-malic acid, D,L-malic acid, oxalic acid, malonic acid, succinic acid, maleic acid, oxalacetic acid, glutaric acid, hydroxyglutaric acid, ketoglutaric acid, adipic acid, ketoadipic acid, pimelic acid, glutamic acid, aspartic acid, phthalic acid, propanetricarboxylic acid, citric acid, isocitric acid, methanesulfonic acid, toluenesulfonic acid and trifluoromethanesulfonic acid.
Compounds of the formula (I) wherein X is represented by NH, S or O may be named as preferred structures. } Preferred embodiments of the compounds of the formula (I) according to the invention are the following compounds of the general formulae (Ia) or (Ib):
Ri 4 joo 6 5
Cr i OC ; NM NON De (1a)
NF ~¢g H n \__/ \ 7> Rs
9 7 PCT/EP2003/007060
Ri 4 roo 6___ 5 ; NO — ¢ (1b) “od Th} wherein: - n=1-4, - R=hydrogen, C;-C¢-alkyl or halogen, - when Rj is hydroxy, C;-Cg-alkyloxy, C,-Cg-alkenyl, C,-Cg-alkinyl, phenyl that may optionally be substituted with a methoxy group or halogen, C;-C¢-acyl, C;-Cg-alkoxy carbonyl or cyano, each of Ry and
R3 are independently selected from hydrogen, hydroxy, C;-Cs- alkyloxy, C;-Cg-alkyl, C,-Cs-alkenyl, C,-Cq-alkinyl, phenyl that may optionally be substituted with a methoxy group or halogen, halogen, trifluoromethyl, C,-Cg-acyl, C,-Cg-alkoxycarbonyl and cyano, - when Ry is hydrogen, C;-Cg-alkyl, halogen or trifluoromethyl, Ry is selected from hydroxy, C,-Cg-alkenyl, C,-Cg-alkinyl, phenyl that may optionally be substituted with a methoxy group or halogen, C;-Cg-acyl,
C,-Cs-alkoxycarbonyl and cyano, and Rj is selected from hydrogen, hydroxy, C;-Cg-alkyl, C;-Cs-alkyloxy, C,-Cg-alkenyl, C,-Cg-alkinyl, phenyl that may optionally be substituted with a methoxy group or halogen, halogen, trifluoromethyl, C;-C4-acyl, C;-Cg alkoxycarbonyl and cyano, and pharmaceutically acceptable salts thereof, fluorine, chlorine and bromine being preferred halogen substituents.
Another preferred embodiment of the compounds of the formula (I) according to the invention are the following compounds of the general formula (Ic):
Ri 4 NE es
Se OE ; NM N IY. (Ic)
ANZA I NEVA
7 H
. @ 3 PCT/EP2003/007060 wherein: : : - n=1-4 - R= hydrogen, C,-Cg-alkyl or halogen, _ Rj is selected from hydrogen, hydroxy, C,-Ce-alkyl, C;-Ce-alkoxy,
C,-Cg-alkenyl, C,-Cg-alkinyl, phenyl that may optionally be substituted with a methoxy group or halogen, trifluoromethyl, C;-Cs-acyl, C;-Cg- alkoxycarbonyl, fluorine, chlorine, bromine and cyano, - each of Rp and Ry are independently selected from hydrogen, hydroxy, . C,-Cg-alkyl, C;-Cg-alkyloxy, C,-Cs-alkenyl, C,-Ce-alkinyl, phenyl that may optionally be substituted with a methoxy group or halogen, halogen, trifluoromethyl, C;-Cs-acyl, C;-Cg-alkoxycarbonyl and cyano, and pharmaceutically acceptable salts of these compounds, with the proviso that the compound is not N-4-(4-(2-methoxyphenyl)piperazine-1-yl)butyl-2- indolylcarbamide.
In another preferred embodiment of the invention, the following applies for compounds of the general formula (Ic): (a) when Rj is hydroxy, C,-Cs-alkenyl, C,-Cg-alkinyl, phenyl that may optionally be substituted with a methoxy group or halogen, trifluoromethyl, C;-Cg-acyl, C;-Cs-alkoxycarbonyl or cyano, each of
Rj and Rj are independently selected from hydrogen, hydroxy, C;-Cs- alkyl, C;-Cg-alkyloxy, C,-Cs-alkenyl, Cp-C¢-alkinyl, phenyl that may optionally be substituted with a methoxy group or halogen, halogen, trifluoromethyl, C,-Cg-acyl, C;-Ce-alkoxycarbonyl and cyano, : and (b) when Rj is hydrogen, C;-Cs-alkyl, C,-Cs-alkyloxy or halogen, Rp 1s selected from hydroxy, C,-Cg-alkenyl, C,-Cg-alkinyl, phenyl that may optionally be substituted with a methoxy group or halogen, C;-Cs-acyl,
C,-C¢-alkoxycarbonyl and cyano, and R3 is selected from hydrogen, hydroxy, Cy-C-alkyl, C-Cg-alkyloxy, Cp-Cs-alkenyl, Cy-Cs-alkinyl, phenyl that may optionally be substituted with a methoxy group or halogen, halogen, trifluoromethyl, C;-Cs-acyl, C;-Cs-alkoxycarbonyl and cyano.
® 9 PCT/EP2003/007060
In another preferred embodiment of the invention, the following applies for the compounds of the formulae (I), (Ia), (Ib), and (Ic): - the substituent R; is in position 5 or 6 of the heterocycle, and - the substituents Ry and Rj are in the positions 2 or 3, respectively, or in the positions 2 or 4, respectively, of the phenyl ring; the respective other substituent being in position 2 of the phenyl ring in the event that ~. one of the two substituents R; and Rj is a hydrogen atom.
In a particularly preferred embodiment of the invention, n = 3 in the compounds of the formulae (I), (Ia), (Ib), and (Ic).
Preferred compounds of the general formula (II) as defined above are those wherein each of Ri and Rj is independently selected from hydrogen, hydroxy,
C;-Cs-alkyloxy, C;-Cg-alkyl, C,-Cs-alkenyl, C,-Ce-alkinyl, aryl, fluorine, chlorine, bromine, trifluoromethyl, C;-Cg-acyl, C;-Cg-alkoxycarbonyl and cyano.
Specific compounds of the general formula (II) are (B16): N-4-(4-(2-methoxyphenyl)piperazine-1-yl)butyl-2-ferrocenylcarbamide and (B17): N-4-(4-(2,3-dichlorophenyl)piperazine-1-yl)butyl-2- ferrocenylcarbamide : Another aspect of the present invention relates to compounds of the general formula (IV):
R
R lo} 6__5 \ AN 3 / \ MRe ; NA ee 20 wm i oN Mw
FX 2 7 wherein: - X=S,NHorO,
. @ pe 10 PCT/EP2003/007060 - R is selected from hydrogen, C;-Cs-alkyl, fluorine, chlorine and bromine, _ Rj is selected from hydrogen, C;-Cs-alkoxy, C;-Ce-alkyl, fluorine, chlorine, bromine, trifluoromethyl and cyano, Rj being in position 5 or : 6 of the heterocycle, _ Rj and Rj are independently selected from hydrogen, C;-Ce-alkyloxy,
C,-C¢-alkyl, fluorine, chlorine, bromine and trifluoromethyl, Ry and R3 being in the positions 2 or 3, respectively, or in the positions 2 or 4, ~. respectively, of the phenyl ring, and the respective other substituent being in position 2 of the phenyl ring in the event that one of the two substituents Ry and R3 is a hydrogen atom and pharmaceutically acceptable salts of this compound with the proviso that the compound is not N-4-(4-(2-methoxyphenyl)piperazine-1-yl)butyl-2- indolylcarbamide.
A preferred aspect of the invention are compounds of the general formula (IV) as defined above, wherein - when X = NH, then Rj is selected from hydrogen, C;-Cs-alkyloxy,
C;-C;s-alkyl, fluorine, chlorine, bromine and cyano, and - when X = S or O, then Rj is selected from hydrogen, C;-Cs-alkyl, fluorine, chlorine, bromine, cyano and trifluoromethyl.
The following compounds are specific embodiments of the compounds according to the invention: (B18): N-4-(4-(2-methoxyphenyl)piperazine-1-yl)butyl-5-cyano-2- benzo[b]thiophenylcarbamide (B19): N-4-(4-(2,3-dichlorophenyl)piperazine-1-yl)butyl-5-cyano-2- benzo[b]thiophenylcarbamide (B20): N-4-(4-(2-methoxyphenyl)piperazine-1 _yl)butyl-6-cyano-2- benzo[b]thiophenylcarbamide (B21): N-4-(4-(2,3-dichlorophenyl)piperazine-1-yl)butyl-6-cyano-2- benzo[b]thiophenylcarbamide
. @ 1 PCT/EP2003/007060
(B1): N-4-(4-(2-methoxyphenyl)piperazine-1-yl)butyl-2-benzo[b]- thiophenylcarbamide
(B2): N-4-(4-(2,3-dichlorophenyl)piperazine-1-yl)butyl-2-benzo[b]- thiophenylcarbamide
(B22): N-4-(4-(2-methoxyphenyl)piperazine-1-yl)butyl-5-bromo-2-
: benzo[b]thiophenylcarbamide
(B23): N-4-(4-(2,3-dichlorophenyl)piperazine-1-yl)butyl-5-bromo-2- benzo[b]thiophenylcarbamide
(B10): N-4-(4-(2,3-dichlorophenyl)piperazine-1-yl)butyl-2-indolylcarbamide
(B11): N-4-(4-(2-methoxyphenyl)piperazine-1-yl)butyl-5-cyano-2- indolylcarbamide
(B12): N-4-(4-(2-methoxyphenyl)piperazine-1-yl)butyl-5-bromo-2-
: indolylcarbamide
(B13): N-4-(4-(2-methoxyphenyl)piperazine-1-yl)butyl-6-cyano-2- indolylcarbamide
(B14): N-4-(4-(2,3-dichlorophenyl)piperazine-1-yl)butyl-5-bromo-2- indolylcarbamide
(B15): N-4-(4-(2,3-dichlorophenyl)piperazine-1-yl)butyl-6-cyano-2- indolylcarbamide
(B25): N-4-(4-(2,3-dichlorophenyl)piperazine-1-yl)butyl-5-cyano-2- indolylcarbamide
(B7): N-4-(4-(2-methoxyphenyl)piperazine-1-yl)butyl-5-cyano-2- benzo[b]furanylcarbamide
(B3): N-4-(4-(2-methoxyphenyl)piperazine-1-yl)butyl-2-benzo[b]- furanylcarbamide
(B4): N-4-(4-(2,3-dichlorophenyl)piperazine-1-yl)butyl-2-
} benzo[b]furanylcarbamide (B5): N-4-(4-(2-methoxyphenyl)piperazine-1-yl)butyl-5-bromo-
benzo[b]furanylcarbamide
(B6): N-4-(4-(2,3-dichlorophenyl)piperazine-1-yl)butyl-5-bromo-2- benzo[b]furanyl-carbamide
(B8): N-4-(4-(2-methoxyphenyl)piperazine-1-yl)butyl-2- benzo[b]tellurophenylcarbamide :
(B9): N-4-(4-(2,3-dichlorophenyl)piperazine-1-yl)butyl-2- benzo[b]tellurophenylcarbamide and pharmaceutically acceptable salts of these compounds.
\ @ 12 PCT/EP2003/007060 @ :
Especially the compounds of the formulae (I), (Ia), (Ib), (Ic), (II) and (IV) as defined above are suitable for therapeutic use as dopamine D3 ligands.
Particular preference is given to compounds of the general formula (I) or pharmaceutically acceptable salts thereof, wherein X = NH, S or O, and to ‘compounds of the formulae (Ia), (Ib), (Ic) and (IV) or pharmaceutically acceptable salts thereof.
The term "D3 ligands with high affinity" comprises compounds which show binding to human dopamine D3 receptors having a Ki value of preferably not more than 10 nM, especially preferably not more than 1 nM, in a radio ligand experiment (cf. Hiibner, H. et al. J. Med. Chem. 2000, 43, 756-762, and the following section "Biological Activity").
One aspect of the present invention relates to selective D3 ligands. The term "selective D3 ligands" comprises compounds with a Ki value in the radio ligand experiment for the D3 receptor as described in the following section "Biological Activity" which is lower by a factor of at least 10 for at least five of the seven following receptors: dopamine receptors D1, D2long, D2short and
D4.4, serotonin receptors 5S-HT1A and 5-HT2 and alpha-1-adrenoreceptor.
Another aspect of the invention relates to dopamine D3 ligands with high selectivity. The term "D3 ligands with high selectivity" comprises compounds with a Ki value in the radio ligand experiment for the D3 receptor as described in the following section "Biological Activity" which is lower by a factor of at least 100 for at least three and preferably all of the of the dopamine receptors - D1, D2long, D2short and D4.4.
D3 ligands may show agonistic, antagonistic or partial-agonistic activity on the
D3 receptor. The respective intrinsic activities of the compounds of the invention may be measured in mitogenesis assays as described in literature (Hiibner, H. et al. J. Med. Chem. 2000, 43, 4563-4569, and Léber, S. Bioorg.
Med. Chem. Lett. 2002, 12.17, 2377-2380). Depending on the pathophysiology of the underlying disease, a stronger agonistic, stronger antagonistic or partial- agonistic activity may be desirable. The present invention therefore permits an excellent fine-tuning of the desired activity.
. 4 13 PCT/EP2003/007060 [
Therefore, a therapeutic agent comprising one or more of the compounds of the general formulae (I), (Ia), (Ib), (Ic), (II) and (IV) or one of the specific compounds as defined above, optionally in the form of a pharmaceutically acceptable salt, is a further subject matter of the invention. Preferably, this includes one or more of the compounds of the general formulae (I), (Ia), (Ib), (Ic) and (IV) or pharmaceutically acceptable salts thereof, wherein X = NH, S or O.
The invention also relates to the use of one or more of the compounds of the general formulae (I), (Ia), (Ib), (Ic), (II) and (IV) or one of the specific compounds listed, optionally in the form of a pharmaceutically acceptable salt, for the treatment, including therapy and prevention, of the indications given here and for preparing a therapeutic agent for said indications.
It is preferred to choose those compounds of the invention which are selective
D3 ligands for preparing therapeutic agents. D3 ligands with high selectivity are especially preferred.
The compounds of the invention have potential use in the therapy or prevention of a number of disorders, especially those accompanied by a dysfunction of the dopamine metabolism or the dopaminergic signal cascade.
Examples for such disorders are cocaine, alcohol, opiate and nicotine addiction; neurodegenerative disorders, especially Parkinson's disease; sexual dysfunction, especially male erectile dysfunction; depression, especially endogenous monophase depression ("major depression") and schizophrenia. : Other examples amenable to therapy or prevention with the compounds of the invention are hyperprolactinaemia; hyperprolactinoma; glaucoma; cognitive disorders; restless leg syndrome; hyperactivity syndrome (ADHS); locomotion disorders associated with Parkinson's disease, e.g. rigor, dystonia and dyskinesia; L-DOPA-induced disorders, such as anxiety, disturbed sleep, psychoses, dyskinesias and dystonias; idiopathic dystonias, especially Segawa syndrome; neuroleptic-induced (tardive) dyskinesia, dystonia and akathisia.
The compounds of the invention are particularly well suited to prepare a therapeutic agent for treating DOPA-sensitive locomotion disorders. Such
. @® 14 PCT/EP2003/007060 [ : locomotion disorders may be dyskinesias, dystonias, rigor and tremor, for example. The term "DOPA-sensitive” is understood to mean that the locomotion disorder may be influenced favourably by the administration of drugs which influence the dopaminergic signal transmission. A typical example is the Segawa syndrome, an idiopathic dystonia where the response to : L-DOPA may be used as a diagnostic criterion.
A preferred use is the preparation of a therapeutic agent for the treatment of dyskinesias and dystonias which may occur spontaneously in connection with
Parkinson's disease, but may also be induced by drugs. Among drug-induced dyskinesias and dystonias, especially those induced by neuroleptics and dopamine antagonists or dopamine agonists or L-DOPA may be mentioned.
In addition, the therapeutic agents may be used in medication-assisted ablactation after a pregnancy.
Finally, the therapeutic agents of the invention may be used as a compound preparation for simultaneous or sequential administration, depending on the disease to be treated.
For example, one unit offered for sale which contains L-DOPA medication for the treatment of Parkinson's disease may also comprise a pharmaceutical preparation which contains one of the compounds of the invention, for example with a high-selectivity, partial-agonistic profile of action. L-DOPA and the compound of the invention may be present in the same pharmaceutical formulation, e.g. a compound tablet or in different units of application, e.g. in - the form of two separate tablets. As needed, the two active ingredients may be : administered simultaneously or at different times
In a compound preparation, sequential administration may be achieved by providing a form of administration, for example an oral tablet, having two different layers with different release profiles for the various pharmaceutically active components. A skilled practitioner will appreciate that various forms of administration and application schemes are conceivable within the context of the invention all of which are subject matters thereof.
9 15 PCT/EP2003/007060 @ :
One embodiment of the invention therefore relates to a therapeutic agent which contains L-DOPA or a neuroleptic as well as a compound of the invention for the simultaneous or sequential administration to a patient.
In general, the therapeutic agents of the invention consist of a pharmaceutical composition which, in addition to the D3 ligands as described above, contains
E at least one pharmaceutically acceptable carrier or excipient.
A skilled practitioner will appreciate that, depending on the intended route of application, the pharmaceutical formulation may take different forms. For example, the pharmaceutical formulation may be adapted for intravenous, intramuscular, intracutaneous, subcutaneous, oral, buccal, sublingual, nasal, , - . transdermal, inhalational, rectal or intraperitoneal administration.
Suitable formulations and pharmaceutical carriers and excipients, respectively, amenable for this purpose such as fillers, disintegrants, binders, lubricants, stabilisers, flavouring agents, antioxidants, preservatives, dispersants or solvents, buffers or electrolytes are known to practitioners skilled in the field of pharmaceuticals and are described in standard works, for example those by
Sucker, Fuchs and Speiser (,,Pharmazeutische Technologie”, Deutscher
Apotheker Verlag, 1991) and Remington ("The Science and Practice of "Pharmacy", Lippincott, Williams & Wilkins, 2000).
In a preferred embodiment of the invention, the pharmaceutical compositions containing the compounds according to the invention may be administered orally and may be present, for example, as a capsule, tablet, powder, granulate, - coated tablet or in liquid form.
The formulation may be prepared as a rapid-release form of administration if fast onset of action is desired. Suitable oral formulations are described in EP 0548 356 or EP 1 126 821. i
If protracted release is desired, on the other hand, a formulation with delayed release of the active ingredient may be selected. Such oral formulations are also known from the prior art.
@ 16 PCT/EP2003/007060 @® :
Alternative pharmaceutical preparations may, for example, be solutions for infusion or injection, oils, suppositories, aerosols, sprays, plasters, micro- capsules or micro-particles.
Another subject matter of the invention is the use of a compound of the general ~ formula (III): : Ri 4 NE 5 5N NX \ SNL ST Re (ii)
J : MAH 7 X n 7 Ra wherein: n=1-4and X=S, O or NH, when R = hydrogen, alkyl or halogen and
Ry are substituted by the radicals hydrogen, alkyl, halogen, trifluoromethyl and each of Ry and Rj is substituted individually or jointly by the radicals hydrogen, hydroxy, alkyloxy, alkyl, alkenyl, alkinyl, aryl, halogen, trifluoromethyl, acyl, alkoxycarbonyl or cyano, for preparing a pharmaceutical agent for the treatment of one of the following diseases or disorders: cocaine, alcohol, opiate and nicotine addiction; schizophrenia; various forms of depression, especially endogenous monophase depression ("major depression") or depressive phases of bipolar (manic-depressive) disorders; neurodegenerative disorders, especially Parkinson's disease; sexual dysfunction; hyperprolactinaemia; hyperprolactinoma; glaucoma; cognitive disorders; restless leg syndrome; hyperactivity syndrome (ADHS); locomotion disorders associated with Parkinson's disease, e.g. rigor, dystonia and dyskinesia; L-DOPA-induced disorders, such as anxiety, disturbed sleep, psychoses, dyskinesias and dystonias; idiopathic dystonias, especially Segawa syndrome; neuroleptic-induced (tardive) dyskinesia, dystonia and akathisia.
In particular, a compound of the general formula (IIT) may be used to prepare a therapeutic agent for the treatment DOPA-sensitive locomotion disorders.
These may occur spontaneously in connection with Parkinson's disease, but may also be induced by drugs. Among drug-induced locomotion disorders,
' ® 17 PCT/EP2003/007060 especially those induced by neuroleptics or dopamine antagonists or L-DOPA- induced dyskinesias and dystonias may be mentioned.
It is preferred to use compounds of the general formula (III) for preparing the therapeutic agents of the invention, wherein - Ris selected from hydrogen, C;-Cg-alkyl, fluorine, chlorine and bromine, - Rj is selected from hydrogen, C;-Cs-alkoxy, C;-C¢-alkyl, fluorine, chlorine, bromine and trifluoromethyl, and - each of Rp and Rj is independently selected from hydrogen, C;-Cs- - alkyloxy, C;-Cg-alkyl, fluorine, chlorine, bromine and trifluoromethyl.
It is also preferred to use compounds of the formula (IIT), wherein - the substituent R; is in position 5 or 6 of the heterocycle, and - the substituents R; and Rj are in the positions 2 or 3, respectively, or in the positions 2 or 4, respectively, of the phenyl ring; the respective other substituent being in position 2 of the phenyl ring in the event that one of the two substituents R; and Rj is a hydrogen atom.
A preferred compound of the general formula (III) for preparing the therapeutic agents of the invention, especially for the treatment of L-DOPA- induced dyskinestas, is the following compound: - (B24): N-4-(4-(2-methoxyphenyl)piperazine-1-yl)butyl-2-indolylcarbamide
The compounds of the formulae (I) bis (IV) were prepared according to methods described in literature (Glennon, R.A et al. J. Med. Chem. 1988, 31, 1968-1971).
For this purpose, acid derivatives of the type (A) which were either available commercially or were synthesised as prescribed in literature were activated in the form of their carboxylic acid chlorides and reacted with the free base of the type (B) to obtain derivatives of the formula (I) (including (Ia), (Ib) and (Ic), (III) or (IV):
. @ 18 PCT/EP2003/007060
R
Ri \ Xx \\ Oo / \ Ty Ro
PMN MAR
FX OH n \__/ 7 "Ry (A) (B) — (I), (1) or (IV) : wherein n, R, Ry, Ry and R3 are as defined above for (I), (III) and (IV), respectively.
As an alternative to the above-mentioned method of activating the acid derivatives, it is possible to use other reactions, for example activation of acids by hydroxyazabenzotriazole (Kienhéfer, A. Synlett 2001, 1811-1812). For : example, the compounds of the formula (II) may be prepared by activating ferrocene-2-carboxylic acid with HATU followed by a reaction with the bases of the type (B).
Commercially available 2-methoxy- or 2,3-dichlorophenyl piperazines may be alkylated with bromobutyl phthalimide in xylene to prepare the aryl piperazinyl amines of the type (B). Subsequent hydrazinolysis of the ) ~ phthalimide-substituted structures provides the primary amines of the type (B).
This is illustrated by the following exemplary reaction scheme:
; ® 19 PCT/EP2003/007060 0
B SE >Re
NT TSF + HN N \ 2 __/ 7 "Ry © 0 /~\ —\_ R,- \ NTN N N \ 2 rian I p xylene nn Rs _MNoHa_ B)(n=3) ethanol
Synthesis of the amines of the type (B) 4-(4-(2,3-dichlorophenyl)piperazine-1-yl)butylamine 2,3 g (10 mmol) of the free base of the 2,3-dichlorophenyl piperazine are dissolved in 10 ml of xylene and heated to 70°C. Then 1.4 g (5 mmol) of 4- bromobutyl phthalimide are dissolved in 20 ml of xylene and slowly dropped into the piperazine solution. The reaction mixture is heated at 125°C for 24 ) hours. After cooling to 0°C, the mixture is filtered and the filtrate evaporated.
The resulting N-4-(4-(2,3-dichlorophenyl)piperazine-1-yl)butylphthalimide is purified by flash chromatography on SiOp with ethyl acetate. Yield: 4.0 g (= 92 %)
A solution of 80 % hydrazine hydrate (0.45 ml, 2.5 eq) in 5 ml of ethanol is dropped into a suspension of N-4-(4-(2,3-dichlorophenyl)piperazine-1- yl)butylphthalimide in 40 ml of ethanol. The mixture is heated at reflux for 3 hours, then cooled to room temperature, the precipitated solid filtered off, and the ethanolic solution evaporated in vacuo.
- @ 20 PCT/EP2003/007060 @
Purification by flash chromatography with CHCly-MeOH-MeEtN:90-8-2 provides the base 4-(4-(2,3-dichlorophenyl)piperazine-1-yl)butylamine in a yield of 900 mg (= 60 %).
MS: m/z 301(M+); IR: (NaCl): 3397; 2939; 2817; 1641; 1572; 1500; 1482; 1452; 1376; 1240; 1152; 1118; 1023; 917; 791; 749; 698; 661. 1H-NMR (CDCl3, 360 MHz) & (ppm): 1.48-1.64 (m, 4H,CH)-CHp); 2.41-2.46 (t, J = 7.6, 2H, CHoN); 2.64 (m, 4H, pip); 2.72-2.76 (m, 2H, CHpNCO); 3.07 (m, 4H, pip); 6.93-6.99 (m, 1H, Hs, phenyl); 7.11-7.17 (m, 2H, Hy, Hg, phenyl).
Example 1
N-4-(4-(2-methoxyphenyl)piperazine-1-yl) butyl-2- - benzo[b]thiophenylcarbamide 0,4 mmol of benzothiophene-2-carboxylic acid (0.071 g) are dissolved in 4 ml of dry toluene and 4 ml of dry chloroform. 0.02 ml of dry DMF and 0.11 ml (1.51 mmol) of SOCI, are added, followed by heating in an oil bath to 90°C for 30 minutes. The solvent is then removed by rotation and dried in a fine vacuum. The acid chloride is dissolved in 40 ml of chloroform and added with stirring at 0°C to a solution of 0.4 mmol of 4-(4-(2-methoxyphenyl)piperazine- 1-yl)butylamine (0.105 g) and 0.17 ml of Et3N in 5 ml of chloroform. After a reaction time of 14 hours, the reaction is washed with aqueous NaHCO3 solution, the organic solvent dried with MgSOy4 and evaporated in vacuo.
Purification by flash chromatography on silica gel CHyCly-MeOH:9-1 provides 114 mg (68 % yield in 2 reaction steps) of N-4-(4-(2- methoxyphenyl)piperazine-1-yl)butyl-2-benzo[b]thiophenylcarbamide.
Smp.: 147°C; MS: m/z 423 (MH); IR (NaCl): 3316; 2938; 2817; 1735; 1629; 1544; 1500; 1241; 1026; 731. IH-NMR (CDCl3, 360 MHz) § (ppm):1.65-1.74 (m, 4H, CHy-CHp); 2.47 (t, 2H, CH2N, J=6.7 Hz); 2.65 (m, 4H, pip); 3.08 (m, 4H, pip); 3.48-3.53 (m, 2H, CHpNCO), 3.85 (s, 3H, OCH3); 6.72 (t, 1H, NH,
J= 4.3 Hz); 6.84-7.01 (m, 4H, phenyl); 7.36-7.44 (m, 2H, Hs, Hg); 7.76 (s, 1H,
Hz); 7.79-7.85 (m, 2H, H7, Hg). 13C-NMR (CDCl3, 90 MHz) 8 (ppm): 162.4; 152.3; 141.2; 140.7; 139.1; 138.7; 126.2; 125.0; 124.9; 122.9; 122.7; 120.9; 118.2; 111.2; 57.9; 55.3; 53.4; 50.5; 40.0; 27.4, 24.3.
C HN (%): C24H29N303S;
. @ 21 PCT/EP2003/007060 ®o
Calc.: C 68.05; H 6.90; N 9.92; S 8.15; Found: C 68.11; H 6.95; N 9.93; S 8.09.
Example 2
N-4-(4-(2,3-dichlorophenyl)piperazine-1-yl)butyl-2- benzo[b]thiophenylcarbamide
Synthesis analogous to example 1.
Yield: 126 mg (68 % in 2 reaction steps)
Smp.: 153°C. MS: m/z 462 (M*). IR (NaCl): 3298; 2967; 2934; 2809; 1640; 1599; 1576; 1530; 1442; 1420; 1301; 1167; 1131; 962; 882; 808; 781; 712.
H-NMR: (CDCl3, 360 MHz) & (ppm): 1.63-1.76 (m, 4H, CH,-CHp); 2.48 (t,
J=6.9 Hz, 2H, CH»N); 2.66 (m, 4H, pip); 3.05 (m, 4H, pip); 3.49-3.54 (m, 2H,
CH)NCO); 6.79 (br, t, J=5.3 Hz, 1H, NH); 6.84-6.86 (dd, J =1.6 Hz, J =7.5
Hz, 1H, phenyl); 7.08-7.16 (m, 2H, phenyl); 7.37-7.44 (m, 2H, Hs, Hg); 7.77- 7.78 (s, 1H, Hz); 7.80-7.90 (m; 2H, Hy, Hy). I13C-NMR (CDCl3, 90 MHz) § (ppm): 157.9; 156.1; 152.3; 151.1; 141.2; 129.9; 127.8; 123.0; 121.0; 118.2; 113.0; 112.3; 106.6; 109.7; 107.9; 57.9; 53.5; 50.5; 39.4; 27.4; 24.3.
CH N (%): C23Hp5CIpN30S
Calc.: C 60.25; H 6.11; N 8.78; Found: C 59.94; H 6.04; N 8.81.
Example 3
N-4-(4-(2-methoxyphenyl)piperazine-1-yl)butyl-2-benzo[b]furanylcarbamide
Synthesis analogous to example 1. : Yield: 75.2 mg (56 % yield % in 2 reaction steps)
Smp.: 121°C. MS: nvz 431 (M1). IR (NaCl): 3311.2; 3060; 2937; 2815; 2216; 1654; 1592; 1500; 1321; 1240; 1178; 1145; 748. IH-NMR (CDCl3, 360 MHz) d (ppm): 1.67-1.74 (m, 4H, CH2-CHj); 2.49 (t, 2H, CH2N, J=6.9 Hz); 2.69 (m, 4H, pip); 3.13 (m, 4H, pip); 3.56-3.50 (m, 2H, CHpNCO); 3.86 (s, 3H,
OCH3); 6.85-6.87 (m, 1H, phenyl); 6.90-6.93 (m, 2H phenyl); 6.99-7.02 (m, 2H, phenyl and NH); 7.26-7.31 (m, 1H, Hg); 7.37-7.42 (m, 1H, Hg); 7.46-7.48 (m, 2H, Hy, Hz); 7.77-7.79 (m, 1H, Hy). 13C-NMR (CDCl3, 90 MHz) & (ppm): 158.9; 154.7; 152.3; 148.9; 141.3; 127.7; 126.7; 123.6; 122.9; 122.7, 120.9; 118.2; 111.7; 111.2; 110.2; 58.0; 55.3; 53.5; 50.5; 39.2; 27.5; 24.3.
’ - 9 22 PCT/EP2003/007060
CHN (%): C24Hy9N303-0.3 H70;
Calc.: C 69.81; H 7.23; N 10.18; Found: C 69.84; H 7.33; N 10.21.
Example 4
N-4-(4-(2,3-dichlorophenyl)piperazine-1-yl)butyl-2-benzo[b]furanylcarbamide
Synthesis analogous to example 1. - Yield: 105 mg (58 % yield in 2 reaction steps)
Smp.: 150°C. MS: m/z 446 (M+). IR (NaCl): 3310; 2939; 2819; 1652; 1595; 1577; 1520; 1448; 1421; 1299; 1257; 1241; 1176; 1141; 1044; 960; 908; 780; 748; 713, 669, 645. IH-NMR (CDCl3, 360 MHz) 8 (ppm): 1.67-1.75 (m, 4H, ~ CHy-CHy); 2.52 (t, J=6.7 Hz, 2H, CH2N); 2.69 (m, 4 H, pip); 3.13 (m, 4H, pip); 3.51-3.56 (m, 2H, CHpNCO); 6.92-6.95 (dd, J=2.3 Hz, 7.3 Hz, 1H, phenyl); 7.00 (brt, J= 4.3 Hz, 1H, NHCO); 7.10-7.17 (m, 2H, phenyl); 7.26- 7.31 (m, 1H, Hy); 7.38-7.43 (m, 1H, Hg); 7.46-7.48 (m, 2H, H3, Hs); 7.66- 7.68 (m; 1H, Hy). 13C-NMR (CDCl3, 90 MHz) § (ppm): 158.9; 154.7; 151.2; 148.2; 134.0; 127.7; 127.5; 127.4; 126.8; 124.6; 123.7; 122.7; 118.6; 111.6; 110.2; 57.9; 53.3; 51.1; 39.2; 27.5; 24.2.
CHN(%): Co3H5CIpN302
Calc.: C 61.89; H 5.65; N 9.41; Found: C 61.74; H 5.86; N 9.05.
Example S
N-4-(4-(2-methoxyphenyl)piperazine-1-yl)butyl-5-brom-2- benzo[b]furanylcarbamide - Synthesis analogous to example 1. 5-Bromo-2-benzo[b]furanylcarboxylic acid was prepared according to literature (Dann, O. Liebigs Ann. Chem. 1986, 438- 455).
Yield: 107.8 mg (56 % yield in 2 reaction steps)
Smp.: 124°C. MS m/z 485 (M1). IR (NaCl): 3450.0; 3289.9; 3068.2; 2927.4, 2765; 1650; 1567, 1535; 1500; 1438; 1238; 1178; 1022; 802; 748. H-NMR (CDCl3, 360 MHz) 8 (ppm): 1.67-1.74 (m, 4H, CH3-CH»); 2.49 (t, J=6.9 Hz, 2H, CHpN); 2.69 (m, 4H, pip); 3.13 (m, 4H, pip); 3.56-3.60 (m, 2H,
CH,NCO); 3.86 (s, 3H, OCH3); 6.85-6.87 (m, 1H, phenyl); 6.91-6.93 (m, 2H, phenyl); 6.97-7.00 (m, 1H, phenyl); 7.00 (brt, J=4.8 Hz, 1H, NH); 7.32-7.35
) @® 23 PCT/EP2003/007060 @ (d, J= 8.9 Hz, 1H, Hy); 7.38-7.39 (m, 1H, Hy); 7.48 (dd, J=8.7 Hz, J=2.0 Hz, 1H, Hg); 7.79-7.80 (m, 1H, Hy). I3C-NMR (CDCl3, 90 MHz) 8 (ppm): 158.4; 153.3; 152.3; 150.1; 141.2; 129.7; 129.6; 125.2; 122.9; 120.9; 120.9; 118.2; 116.7; 113.1; 111.2; 109.4; 64.8; 57.9; 55.3; 53.5; 50.4; 39.3; 27.5; 24.3.
CHN (%): Co4H29BrN30g; “Calc.: C 59.26; H 5.80; N 8.64; Found: C 59.05; H 5.81; N 8.68.
Example 6
N-4-(4-(2,3-dichlorophenyl)piperazine-1-yl)butyl-5-bromo-2- benzo[b]furanylcarbamide
Synthesis analogous to example 5. © Yield: 102 mg (47 % yield in 2 reaction steps)
Smp.: 145°C. MS m/z 524 (MT); IR (NaCl): 3400; 2937; 2815; 2227, 1666; 1594; 1527; 1500; 1294; 1240; 1141; 1118; 1025; 842; 746. 1H-NMR (CDCl3, 360 MHz) 8 (ppm): 1.63-1.74 (m, 4H, CH2-CH)3); 2.49-2.52 (t, J=6,7
Hz, 2H, CH)N); 2.68 (m, 4H, pip); 3.09 (m, 4H, pip); 3.49-3.56 (m, 2H,
CHoNCO); 6.92-6.94 (dd, J=2.1 Hz, J=7.5 Hz, 1H, phenyl); 6.98-7.01 (brt,
J=3,0 Hz, 1H, NH); 7.33-7.36 (d, J = 5.3 Hz, 1H, Hy); 7.39 (m, 1H, H3); 7.48- 7.51 (dd, J=8.7 Hz, J=2.0 Hz, 1H, Hg); 7.80-7.81 (d, J=2.0 Hz; 1H, Hy). 13C-
NMR (CDCl3, 90 MHz) & (ppm): 157.9; 156.1; 152.3; 151.1; 141.2; 129.9; 127.8; 123.0; 121.0; 118.2; 113.0; 112.3; 106.6; 109.7; 107.9; 57.9; 55.4; 53.5; 50.5; 39.4; 27.4; 24.3; 21.0.
C H N(%): Co3Hp4BrClpN309
Calc.: C 52.57; H4.67, N 8.03; Found: C 52.63; H 4.67; N 8.03.
Example 7
N-4-(4-(2-methoxyphenyl)piperazine-1-yl)butyl-5-cyano-2- benzo[b]furanylcarbamide 0.37 mmol (141 mg) of HATU and 0.37 mmol (69 mg) of the 5-cyano-2- benzo[b]furanylcarboxylic acid (Dann, O. Liebigs Ann. Chem. 1986, 438-455) are dissolved in 1 ml of DMF at 0°C and 0,74 mmol (0,13 ml) of DIEA are added. Then 0.33 mmol (87 mg) of 4-(4-(2-methoxyphenyl)piperazine-1- yl)butylamine is dissolved in DMF and dropped into the reaction solution at 0°C. After one hour, the reaction is taken up in CHCl3 and washed with
- @ 24 PCT/EP2003/007060 @
NaHCOj3 solution and water. After drying with MgSQOy4, the solvent is evaporated and purified by flash chromatography (SiO2; petroleum ether-ethyl acetate: of 1-1 after ethyl acetate).
Yield: 41 mg (28 %) ‘Smp.: 96°C. MS m/z 432 (M+). IR (NaCl): 3400; 2937; 2815; 2227; 1666; 1594; 1527; 1500; 1294; 1240; 1141; 1118; 1025; 842; 746. H-NMR (CDCl3, 360 Mhz) § (ppm): 1.67-1.74 (m, 4H, CH2-CHp); 2.49 (t, J=6.9 Hz, 2H, CH2N); 2.69 (m, 4H, pip); 3.13 (m, 4H, pip); 3.56-3.60 (m, 2H,
CH,NCO); 3.86 (s, 3H, OCH3); 6.84-7.02 (m, 4H, phenyl); 7.12-7.15 (brt,
J=5.1 Hz, 1H, NH); 7.50-7.51 (m, 1H, Hy); 7.55-7.57 (m, 1H, H3); 7.65-7.68 (m, 1H, Hg); 8.03-8.04 (m, 1H, H7). 13C-NMR (CDCl3, 90 MHz) 8 (ppm): 157.9; 156.1; 152.3; 151.1; 141.2; 129.9; 127.8; 123.0; 121.0; 118.2; 113.0; 112.3; 106.6; 109.7; 107.9; 57.9; 55.4; 53.5; 50.5; 39.4; 27.4; 24.3; 21.0.
Example 8
N-4-(4-(2-methoxyphenyl)piperazine-1-yl)butyl-2- benzo[b]tellurophenylcarbamide
Synthesis analogous to example 7.
Yield: 73 mg (58 %)
Smp.: 85°C. MS m/z 521 (M1). IR (KBr): 3320; 3047; 2933; 2815; 1616; 1566; 1541; 1375; 1498; 1240; 1023; 748. H-NMR (CDCl3, 360 MHz) § (ppm): 1.62-1.66 (m, 4H, CH,-CHy); 2.42-2.45 (t, J= 6.7 Hz, 2H, CH)N);, 2.63 (m, 4H, pip); 3.04 (m, 4H, pip); 3.38-3.43 (m, 2H, CHpNCO); 3.78 (s, ) 3H, OCH3); 6.70-6.76 (brt, J= 4.3 Hz, 1H, NH); 6.77-6.83 (m, 3H, phenyl); 6.94-6.96 (m, 1H, phenyl); 7.09-7.14 (m, 1H, Hg); 7.28-7.32 (m, 1 H, Hs); 7.74-7.76 (d, J=1,5 Hz, 1H, Hy); 7.84-7.86 (d, J =7.8 Hz, 1H, H7); 8.13 (s, 1H,
H3). 13C-NMR (CDCl3, 90 MHz) § (ppm): 166.1; 152.3; 147.9; 141.2; 140.2; 134.8; 132.3; 129.3; 125.8; 125.5; 122.9; 121.0; 118.2; 111.2; 57.9; 55.3; 53.3; 50.5; 40.4; 27.4; 24 4.
Example 9
N-4-(4-(2,3-dichlorophenyl)piperazine-1-yl)butyl-2- benzo[b]tellurophenylcarbamide
- @ 25 PCT/EP2003/007060 @
Synthesis analogous to example 7. :
Yield: 92 mg (45 %)
Smp.: 92°C. MS m/z 560 (M1). IR (NaCl) : 3288; 2938; 2819; 1651; 1578; 1557; 1448; 1242; 1044; 734. IH-NMR (CDCl3, 360 MHz) § (ppm): 1.63- ‘1.74 (m, 4H, CH2-CHj); 2.48-2.52 (t, J=7.1 Hz, 2H, CH)N); 2.66 (m, 4H, pip); 3.05 (m, 4 H, pip); 3.46-3.51 (m, 2H, CHaNCO); 6.70-6.72 (brt, J= 4.8
Hz, 1H, NH); 6.83-6.86 (dd, J=1.8 Hz, J=7.8 Hz, 1H, phenyl); 7.07-7.22 (m, 3H, phenyl, Hg); 7.36-7.41 (m, 1H, Hs); 7.81-7.83 (d, J=7.6 Hz, 1H, Hy); 7.91-7.94 (4, J=7.6 Hz, 1H, H7); 8.17 (m, 1H, Hz). I3C-NMR (CDCl3, 90
MHz) & (ppm): 166.1; 151.1; 147.9; 140.2; 135.0; 134.9; 134.0; 132.3; 129.2; 127.5; 127.4; 125.8; 125.5; 124.6; 118.6; 58.0; 53.3; 51.2; 40.4; 27.5; 24.4. E
Example 10
N-4-(4-(2,3-dichlorophenyl)piperazine-1-yl)butyl-2-indolylcarbamide
Synthesis analogous to example 1.
Yield: 48 mg (58 % yield in two reaction steps)
Smp.: 148°C. MS m/z 444 (M™). IR (NaCl): 3258, 3059; 2938; 2821; 1636; 1577; 1555; 1507; 1448; 1420; 1308; 1241; 1139; 1044; 961; 908; 779; 747, 733; 669; 647. JH-NMR (CDCl3, 360 MHz) & (ppm): 1.67-1.74 (m, 4H, CHp-
CH»); 2.47-2.51 (t, J=6.9 Hz, 2H, CH)N); 2.67 (m, 4H, pip); 3.13 (m, 4H, pip); 3.53-3.55 (m, 2H, CH7pNCO); 6.59-6.66 (brt, J=4.3 Hz, 1H, NHCO); 6.85 (s, 1H, Hz); 6.90-6.93 (m, 1H, phenyl); 7.07-7.17 (m, 3H, phenyl, Hs); 7.28- 7.30 (m, 1H, Hg); 7.43-7.46 (m, 1H, Hy); 7.62-7.65 (m, 1H, Hy); 9.56 (s, 1H, - NH). I3C-NMR (CDCl3, 90 MHz) & (ppm): 161.7; 160.4; 151.1; 136.2; 134.0; 130.9; 127.5; 127.4; 121.8; 120.8; 118.5; 111.9; 101.8; 68.2; 57.9; 53.3; 51.1; 39.5; 27.5; 24.3.
Example 11
N-4-(4-(2-methoxyphenyl)piperazine- 1-yl)butyl-5-cyan-2-indolylcarbamide
Synthesis analogous to example 7.
Yield: 109 mg (42 %)
- @ 26 PCT/EP2003/007060
Smp.: 170°C. MS m/z 431 (M1). TH-NMR (CDCl3, 360 MHz) & (ppm): 1:74- 1.78 (m, 4H, CHy-CHp); 2.54-2.65 (t, J =6.7 Hz, 2H; CH2N); 2.79 (m, 4H, pip); 3.17 (m, 4H, pip); 3.55-3.59 (m, 2H, CHpNCO); 3.85 (s, 3H, OCH3); 6.84-6.87 (d, J=8.5 Hz, 1H, Hs); 6.88-6.90 (m, 3H, phenyl); 6.99-7.05 (m, 2H, phenyl, Hy); 7.07-7.12 (brt, J=3.9 Hz, 1H, NHCO); 7.47-7.50 (dd, J=1.4 Hz,
J=8.5 Hz, 1H, Hg); 7.52-7.54 (d, J= 8.5 Hz, 1H, Hy); 8.01 (s, 1H, H3); 10.14 (s, 1H, NH). 13C-NMR (CDCl3, 90 MHz) & (ppm): 152.2; 140.7; 137.7 133.3; 127.8; 127.3; 126.7; 123.4; 121.1; 120.2; 118.3; 111.3; 103.9; 102.9; 57.6; 55.4; 53.5; 50.0; 39.2; 27.0; 24.2.
Example 12
N-4-(4-(2-methoxyphenyl)piperazine-1-yl)butyl-5-bromo-2-indolylcarbamide :
Synthesis analogous to example 7.
Yield: 112 mg (60%)
Smp.: 188°C. H-NMR (CDCl3, 360 MHz) & (ppm): 1.64-1.74 (m, 4H, CHp-
CH»); 2.46-2.51 (t, J=7.1 Hz, 2H, CHpN); 2.68 (m, 4H, pip); 3.12 (m, 4H, pip); 3.49-3.64 (m, 2H, CHpNCO); 3.83 (s, 3H, OCH3); 6.68-6.71 (brt, J=5.3
Hz, 1H, NHCO); 6.76-6.77 (d, J=1.8 Hz, 1H, Hy); 6.85-6.87 (d, J=7.8 Hz, 1H, phenyl); 6.92-6.93 (d, J= 3.9 Hz, 2H, phenyl); 6.98-7.03 (m, 1H, phenyl); 7.31-7.38 (m, 2H, Hg, H7); 7.76-7.77 (m, 1H, H3); 9.64 (s, 1H, NH).
Example 13
N-4-(4-(2-methoxyphenyl)piperazine-1-yl)butyl-6-cyan-2-indolylcarbamide - Synthesis analogous to example 1.
Yield: 112 mg (58 % yield in 2 reaction steps)
Smp.: 174°C. MS m/z 431 (M1). IR (NaCl): 2940; 2909; 2803; 2753; 2216; 1645; 1548; 1498; 1321; 1237; 1148; 820; 754; 742. H-NMR (CDCl3, 360
MHz) & (ppm): 1.67-1.82 (m, 4H, CH-CHj); 2.47-2.51 (t, J=6.7 Hz, 2H,
CH N); 2.66 (m, 4H, pip); 3.68-3.70 (m, 2H, CHpNCO); 3.85 (s, 3H, OCH3); 3.09 (m, 4H. pip); 6.84-6.94 (m, 4H, phenyl, H3); 6.99-7.02 (m, 1H, phenyl); 7.13-7.16 (brt, J= 5.5 Hz, 1H, NHCO); 7.31-7.34 (m, 1H, Hs); 7.67-7.69 (d,
J=8.5 Hz, Hy); 7.84 (s, 1H, Hy); 11.22 (s, 1H, NH). 13C-NMR (CDCl3, 90
MHz) § (ppm): 161.2; 152.2; 141.1; 135.2; 134.3; 130.5; 123.0; 122.9; 122.7;
- @ 27 PCT/EP2003/007060 @o 120.9; 120.2; 118.1; 117.4; 111.2; 106.6; 102.2; 57.8; 55.3; 53.8; 53.4; 50.4; 39.8; 30.1; 27.3; 24.3.
CHN (%): C25HagN502:1.4 HO;
Calc.: C 65.74; H 7.02; N 15.33; Found: C 65.98; H 7.30; N 14.87
Example 14
N-4-(4-(2,3-dichlorophenyl)piperazine-1-yl)butyl-5-brom-2-indolylcarbamide 0,24 mmol (58 mg) of HATU, 0,24 mmol of HOAt (33 mg) and 0,24 mmol (69 mg) of the 5-bromine-2-indolcarboxylic acid are dissolved in 5 ml of DMF at 0°C in 5 ml of DMF and 0,48 mmol (0,094 ml) DIEA are added. Then 0.26 mmol (78 mg) of 4-(4-(2,3-dichlorophenyl)piperazine-1-yl)butylamine are : : dissolved in DMF and dropped into the reaction solution at 0°C. After three hours, the reaction is taken up in CHCl3 and washed with NaHCO3 solution and water. After drying with MgSQOg, the solvent is evaporated and purified by flash chromatography (SiOp; CHCl3:MM, 98:2). Yield: 94 mg (74 %)
MS mvz 524 (M71). IR (NaCl): 3234; 2932, 2821; 1637; 1577; 1545; 1282; 1046; 733. 1H-NMR (CDCl3, 360 MHz) & (ppm): 1.57-1.73 (m, 4H, CHp-
CHpy); 2.51 (t, J=6.9 Hz, 2H, CH3N); 2.66 (m, 4H, pip); 3.07 (m, 4H, pip); 3.51-3.63 (m, 2H, CHpNCO); 6.64 (brt, J=5.3 Hz, 1H, NHCO); 6.77 (d, J=1.8
Hz, 1H, phenyl, Hyg); 6.90 (dd, J=2.1 Hz, J=7.5 Hz. 1H, phenyl); 7.10-7.17 (m, 2H, phenyl); 7.31-7.38 (m, 2H. Hg. H3); 7,76-7,77 (m, 1H, H7); 9.68 (s, 1H,
NH).
Example 15 - N-4-(4-(2,3-dichlorophenyl)piperazine- 1-yl)butyl-6-cyano-2-indolylcarbamide
Synthesis analogous to example 7.
Yield: 102 mg (59 %)
Smp.: 174°C. MS m/z 470(M™). IR (NaCl): 3215; 2926; 2821; 1634; 1570; 1506; 1239; 1034; 734. IH-NMR (CDCl3, 360 MHz) § (ppm): 1.69-1.82 (m, 4H, CHy-CH)); 2.51 (t, J=6.9 Hz, 2H, CH)N); 2.66 (m, 4H, pip); 3.06 (m, 4H, pip); 3.58-3.63 (m, 2H, CHpNCO); 6.85 (brt, J= 5.5 Hz, 1H, NHCO); 6.88- 6.91 (m, 2H, phenyl, H3); 7.09-7.17 (m, 2H, phenyl); 7.35 (dd, J=1.4 Hz,
- @ 28 PCT/EP2003/007060
J=8.2 Hz, 1H, Hs); 7.70 (d, J=8.5 Hz, H4); 7.84 (s, 1H, Hy); 10.65 (s, 1 H,
NH).
Example 16
N-4-(4-(2-methoxyphenyl)piperazine-1-yl)butyl-2-ferrocenylcarbamide
Synthesis analogous to example 7.
Yield: 155 mg (71 %)
MS m/z 475 (M1). IR (NaCl): 3318, 2939, 2816, 1630, 1543, 1500, 1241, 1027, 748. 1H-NMR (CDCl3, 360 MHz) & (ppm): 1.66-1.69 (m, 4H, CHj-
CHp); 2.57 (t, J=6.7 Hz, 2H, CH)N); 2.77 (m, 4H, pip); 3.16 (m, 4H, pip); IE ~ 3.39-3.44 (m, 2H, CHaNCO); 3.86 (s, 3H, OCH3); 4.17-4.21 (m, 3H, Fer); 4.32-4.33 (m, 2H, Ferr); 4.68-4.69 (m, 2H, Ferr); 6.02 (brt, J=5.3 Hz, 1H, NH); 6.85-6.94 (m, 3H, phenyl); 6.99-7.03 (m, 1H, phenyl). 13C-NMR (CDCl3, 90
MHz) § (ppm): 170.3; 152.2; 140.9; 123.1; 120.9; 118.3; 111.2; 77.2; 76.3; 70.3; 69.7; 68.1; 57.9; 55.3; 53.4; 50.1; 39.2; 27.7; 23.8.
Example 17
N-4-(4-(2,3-dichlorophenyl)piperazine- 1-yl) butyl-2-ferrocenylcarbamide
Synthesis analogous to example 7.
Yield: 85 mg (69 %)
MS m/z 514 (M1). IH-NMR (CDCl3, 360 MHz) § (ppm): 1.63-1.66 (m, 4H,
CH,-CH»); 2.48 (t, J=6.9 Hz, 2H, CH)N); 2.65 (m, 4H, pip); 3.08 (m, 4H, - pip); 3.39-3.44 (m, 2H, CHpNCO); 4.17-4.21 (m, 3H, Ferr); 4.33-4.34 (m, 2H,
Ferr); 4.64-4.65 (m, 2H, Ferr); 5.38 (brt, J=5.1 Hz, 1H, NH); 6.92-6.98 (m, 1H, phenyl); 7.11-7.17 (m, 2H, phenyl).
Example 18
N-4-(4-(2-methoxyphenyl)piperazine-1-yl)butyl-5-cyano-2- benzo[b]thiophenylcarbamide : 0.012 mmol (94 mg) of HATU and 0,012 mmol (25 mg) of the 5-cyano-2- benzo[b]thiophene carboxylic acid (Bridges, A. J. Tetr. Lett. 1992, 7499-7502) are dissolved in 1 ml of DMF and 4 ml of CH,Cl, at 0°C and 0,024 mmol
- @ 29 PCT/EP2003/007060 @ (0,06 ml) of DIEA added. Then 0.013 mmol (34 mg) of 4-(4-(2- methoxyphenyl)piperazine-1-yl)butylamine are dissolved in CHClp and dropped into the reaction solution at 0°C. After two hours, the reaction is taken up in CHCl3 and washed with NaHCO3 solution and water. After drying with
MgSOy4, the solvent is evaporated and purified by flash chromatography (S109; methylene chloride-methanol: 98-2). © Yield: 60 mg (91%)
Smp.: 147°C. MS m/z 448 (MM. IR (KBr): 3336; 2929; 2816; 2225; 1635; 1500; 1240; 1028; 750. "H-NMR (CDCl;, 360 MHz) 8 (ppm): 1.73-1.77 (m, 4H, CH,-CHy,); 2.59 (t, J=6.4 Hz, 2H, CH,N); 2.78 (m, 4H, pip); 3.14 (m, 4H, pip); 3.49-3.53 (m, 2H, CH,NCO) , 3.85 (s, 3H, OCHj3); 6.84-6.92 (m, SH, - phenyl, NH); 6.99-7.04 (m, 1H, phenyl); 7.60 (dd, J=1.4 Hz, J=8.5 Hz, 1H,
He); 7.88 (s, 1H, Hj); 7.95 (d, J=8.5 Hz, 1H, Hy); 8.12 (d, J=1.1 Hz. 1H, Hy). 13C.NMR (CDCls, 90 MHz) & (ppm): 170.3; 152.2; 140.9; 123.1; 120.9; 118.3; 111.2; 77.2; 76.3; 70.3; 69.7; 68.1; 57.9; 55.3; 53.4; 50.1; 39.2; 27.7; 23.8.
C HN (%) C,sH,5sCLNsO- 1H, 0;
Calc.: C64.35H 6.48 N 12.01 S 6.87; Found: C 64.59 H6.13 N 11.77 S 6.44.
Example 19
N-4-(4-(2,3-dichlorophenyl)piperazine-1-yl)butyl-5-cyan-2- benzo[b]thiophenylcarbamide
Synthesis analogous to example 18.
Yield: 57 mg (96 %) - Smp.: 190°C. MS m/z 487 (M"). IR (KBr): 3319; 2929; 2819; 2227; 1633; 1560; 1448; 1242; 1045; 755. "H-NMR (CDCl,, 360 MHz) 3 (ppm): 1.65-1.76 (m, 4H, CH,-CH,); 2.49 (t, J=6.7 Hz, 2H, CH,N); 2.65 (m, 4H, pip); 3.04 (m, 4H, pip); 3.49-3.55 (m, 2H, CH,NCO); 6.78 (br, t, J=5.0 Hz, 1H, NH); 6.85 (dd J=1.8 Hz, J=7.8Hz, 1H, phenyl); 7.09-7.17 (m, 2H, phenyl); 7.62 (dd,
J=1.4 Hz, J=8.5 Hz, 1H, Hy); 7.77 (s, 1H, H;); 7.95 (d, J=8.2 Hz, H;); 8.13 (d,
J=1.4 Hz, 1H, H,). :
BC-NMR (CDCl;, 90 MHz) 8 (ppm): 161.4; 151.1; 144.5; 142.0; 138.8, 134.1; 129.4, 127.9; 127.5, 127.4; 124.7; 123.9; 123.8; 118.9; 118.4; 108.9; 57.9; 53.3; 51.2; 40.2; 27.4; 24.3.
C HN (%) C,0H26C1,N,0 S-1.46 H,0O
_ 30 PCT/EP2003/007060
Calc.: C 56.11 H 5.28 N 10.90; Found: C 56.51 H 5.06 N 10.45. :
Example 20
N-4-(4-(2-methoxyphenyl)piperazine-1-yl)butyl-6-cyano-2- benzo[b]thiophenylcarbamide
Synthesis analogous to example 18.
Yield: 30 mg (43%)
Smp.: 124°C. MS m/z 448 (M"). IR (KBr): 3290; 2937; 2816; 2225; 1619; 1543; 1500; 1242; 1026; 751. "H-NMR (CDCl;, 360 MHz) & (ppm): 1.72-1.90 LT ~ (m, 4H, CH,-CH,); 2.90 (t, ]=7.3 Hz, 2H, CH,N); 3.15 (m, 4H, pip); 3.31 (m, 4H, pip); 3.50-3.56 (m, 2H, CH,NCO), 3.82 (s, 3H, OCH3); 6.84- 6.92 (m, 3
H, phenyl); 7.01-7.07 (m, 1H, phenyl); 7.13 (br, t, J=5.7, 1H, NH); 7.53 (dd,
J=1.4 Hz, J=8.2 Hz, 1H, Hs); 7.84 (d, J=7.8 Hz, 1H, Hy); 7.84 (s, 1H, Hj); 8.10-8.11 (m, 1H, H,). ®C-NMR (CDCl;, 90 MHz) § (ppm): 161.5; 152.3; 141.9; 141.0; 140.4; 127.5; 127.4. 125.6; 124.2; 123.1. 120.9; 118.8; 118.1; 111.3; 109.5; 77.2; 76.3; 70.3; 69.7; 68.1; 57.9; 55.3; 53.4; 50.4; 40.1; 27.3, 24.2.
Example 21
N-4-(4-(2,3-dichlorophenyl)piperazine-1-yl)butyl-6-cyano-2- benzo[b]thiophenylcarbamide
Synthesis analogous to example 18. - Yield: 26 mg (43 %)
Smp.: 137°C. MS m/z 486 (M"). IR (KBr): 3335; 2933; 2821; 2226; 1638; 1544; 1448; 1242; 1044; 735. "H-NMR (CDCl;, 360 MHz) § (ppm): 1.67-1.74 (m, 4H. CH,-CH,); 2.49 (t, J=6.4 Hz, 2H, CH,N); 2.65 (m, 4H, pip); 3.04 (m, 4H, pip); 3.49-3.54 (m, 2H, CH,NCO); 6.75 (br, t, J= 4.1 Hz, 1H, NH); 6.84 (dd, J=1.8 Hz, 7.8 Hz, 1H, phenyl); 7.08-7.17 (m, 2H, phenyl); 7,60-7,62 (m, 1H, Hs); 7.78 (s, 1H, H;); 7.88-7.90 (m, 1H,H,); 8.19 (br, s, 1H, Hy).
BC.NMR (CDCls, 90 MHz) § (ppm): 161.4; 151.1; 143.6; 141.8; 140.3; 134.1; 127.5; 127.4; 125.2; 124.7. 124.2; 118.7; 118.4; 109.5; 109.5; 58.0; 53.3; 51.3; 51.2; 40.3; 27.4; 24.3.
@ 31 PCT/EP2003/007060 @
C HN (%): C,4H,5ClI;,Ns0-H,0; :
Calc.: C 59.02; H 5.57; N 14.34. Found: C 58.76; H 5.30; N 14.19.
Example 22
N-4-(4-(2-methoxyphenyl)piperazine-1-yl)butyl-5-brom-2- benzo[b]thiophenylcarbamide
B Synthesis analogous to example 7.
Yield: 73 mg (58%)
Smp.: 156°C. MS m/z 502 (M'). IR (KBr): 3316; 2934; 2821; 1633; 1558; 1500; 1242; 1026; 750. "H-NMR (CDCl;, 360 MHz) & (ppm): 1.69-1.72 (m, IE . 4H,CH,-CH,); 2.57 (t, J=6.5 Hz, 2H, CH,N); 2.77 (m, 4H, pip); 3.12 (m, 4H, pip); 3.49-3.51 (m, 2H, CH,NCO); 3.85 (s, 3 H, OCH); 6.83-6.91 (m, 4H, phenyl); 7.01-7.06 (m, 1H, phenyl); 7.15 (brt, J=4.9 Hz, 1H, NH); 7.42 (dd,
J=8.5 Hz, J=1.8 Hz, 1H, Hg); 7.60 (d, J=8.5 Hz, 1H, H,); 7.73 (s, 1H, H;); 7.86 (d, J=1.7 Hz, 1H, H,). C-NMR (CDCl;, 90 MHz) § (ppm): 170.3; 152.2; 140.9; 123.1; 120.9; 118.3; 111.2; 77.2; 76.3; 70.3; 69.7; 68.1; 57.9; 55.3; 53.4; 50.1; 39.2; 27.7; 23.8.
CHN: C,,H,3BrN;0,S (%): Calc.: C 57.37 H 5.62 N 8.36; Found: C 65.98 H 7.30N 14.87.
Example 23
N-4-(4-(2,3-dichlorophenyl)piperazine- 1-yl) butyl-5-brom-2- benzo[b]thiophenylcarbamide . Synthesis analogous to example 7.
Yield: 78 mg (60 %)
Smp.: 178°C. MS m/z 541 (M"). IR (KBr; ): 3316; 2929; 2821; 1631; 1560; 1242; 1068; 756. 'H-NMR (CDCl;, 360 MHz) & (ppm): 1.63-1.69 (m, 4H,CH,-CH,); 2.48 (t, J=6.7 Hz, 2H, CH;N); 2.64 (m, 4H, pip); 3.04 (m, 4H, pip); 3.48-3.53 (m, 2H, CH,NCO); 6.71 (br, t, J=5.1 Hz, 1H, NH); 6.83-6.86 (m, 1H, phenyl); 7.09-7.17 (m, 2H, phenyl); 7.51 (dd, J=1.8 Hz. J=8.5 Hz, 1H,
Hg); 7.67 (s. 1H, Hs); 7.72 (d, J=8.5 Hz, 1H, H;); 7.95 (d, J=1.8 Hz, 1H, H,).
- @ 32 PCT/EP2003/007060 @ 3C.NMR (CDCl;, 90 MHz) § (ppm): 161.9; 160.8; 140.7; 140.6. 139.2; 134.1; 129.3; 127.4; 127.3; 124.6; 124.1; 123.8. 118.9; 118.5; 57.9; 55.3; 51.2; 40.2; 27.5; 24.4.
C HN (%): Cy3H,4BrCI;N;0S-0.25H,0;
Calc.: C 50.61 H4.52 N 7.70 S 5.87; Found: C 50.61 H4.49N 7.64 S 5.87.
Example 24
N-4-(4-(2-methoxyphenyl)piperazine-1-yl)butyl-2-indolylcarbamide
Synthesis analogous to example 7.
Yield: 89 mg (55 %) -
MS m/z 406 (M). IR (NaCl): 3251; 3055; 2935; 2809; 1639; 1549; 1241; 1016; 746. "H-NMR (CDCl;, 360 MHz) & (ppm): 1.67-1.74 (m, 4H,CH,-CH3); 2.48 (t, J=6.7 Hz, 2H, CH,N); 2.67 (m, 4H, pip); 3.11 (m, 4H, pip); 3.51-3.56 (m, 2H, CH,NCO); 3.85 (s, 1H, OCHj;); 6.59 (br, t, J= 4.9 Hz, 1H, NHCO); 6.83-6.94 (m, 3H, phenyl); 6.97-7.02 (m, 1H, phenyl); 7.11-7.15 (m, 1H, Hs); 7.25 (s, 1H, Hy); 7.29 (dd, J=1.1 Hz, J=7.1 Hz, 1H, Hg); 7.43 (d, J=8.9 Hz, 1H,
H,); 7.63 (d, J=8.9 Hz, 1H, H,); 9.50 (s, 1H).
Example 25
N-4-(4-(2,3-dichlorophenyl)piperazine-1-yl)butyl-5-cyano-2-indolylcarbamide
Synthesis analogous to example 7.
Yield: 102 mg (59 %)
Smp.: 96°C. MS m/z 470 (M"). IR (KBr): 3315; 2926; 2821; 2218, 1634; 1570; 1506; 1239; 1043; 734. "H-NMR (CDCl;, 360 MHz) § (ppm): 1.69-1.82 (m, 4H, CH,-CH,); 2.51 (t, J=6.9 Hz, 2H, CH,N); 2.66 (m, 4H, pip); 3.06 (m, 4H, pip); 3.58-3.63 (m, 2H, CH,NCO); 6.85 (br, t,, J=5.5 Hz, 1H, NHCO);, 6.88-6.91 (m, 2H, phenyl, H;); 7.09-7.17 (m, 2H, phenyl); 7.35 (dd, J=1.4 Hz,
J=8.2 Hz, 1H, Hs); 7.70 (d, J=8.5 Hz, Hy); 7.84 (s, 1H, H;); 10.65 (s, 1H, NH).
BBC-NMR (CDCl;, 90 MHz) § (ppm): 161.2; 151.1; 135.2; 134.3; 134.0; 130.5; 127.5; 127.4; 124.6; 123.1; 122.8; 120.1; 118.5; 117.2; 106.9; 102.0; 58.7; 53.3; 51.2; 41.1; 39.9; 24.4.
C H N (%): C1H;5sC1,N50-H, 0; :
@ 33 PCT/EP2003/007060 @®
Calc.: C 59.02; H5.57; N 14.34. Found: C 58.76; H 5.30; N 14.19. :
BIOLOGICAL ACTIVITY
The biological activities of the compounds of the invention were determined in radio ligand binding assays. All radio ligand experiments were carried out in accordance with methods described by us (Hiibner, H. et al. J. Med. Chem. 2000, 43, 756-762). For the measurement of the affinities to the receptors of the D2 family, membrane homogenates of ovarian cells of the Chinese hamsters (CHO cells) were used each of which stably expressed the human
D2long-, the human D2short- (Hayes, G. et al. Mol. Endocrinol. 1992, 6, 920- 926), the human D3- (Sokoloff, P. et al. Eur. J. Pharmacol. 1992, 225, 331- 337) or the human D4.4-receptor subtype (Asghari, V. J. Neurochem. 1995, 65, 1157-1165). In general, the binding assays were carried out by incubation of the receptor homogenates with the radio ligand [*H]Spiperon and the compound to be tested in different concentrations. The affinities to the D1 receptor were determined with native membrane homogenates obtained from the striatum of a pig and with the D1-selective radio ligand [’H]SCH 23390.
For the purpose of determining the binding strengths of the compounds to the serotonin receptor subtypes 5-HT1A and 5-HT2 cortex membrane preparations of a pig were incubated with the radio ligands [*H]8-OH-DPAT (for 5-HT1A) or [*H]Ketanserin (5-HT2) and the compounds. Indications of a simultaneous binding of the compounds to the serotonergic 5-HT2 receptor and to the adrenergic receptor subtype al upon labelling with the radio ligand [PH]Ketanserin were confirmed in a parallel experiment with selective : blocking of the al receptor by Prazosin. Therefore Ki values determined in the presence of 10 uM of Prazosin represent the sole bond to the 5-HT2 receptor.
In addition, the affinity to al receptors of the pig were determined in a separate experiment with the al-selective radio ligand [’H]Prazosin.
The results of the receptor binding assays on the dopamine receptor subtypes are summarised in table 1. : ~All of the compounds tested in the binding assay showed good to very good affinities to the dopamine receptors with a clear binding preference to the subtypes of the D2 family. Independently of the partial structure, a clear
- @ | 34 PCT/EP2003/007060 @ selectivity to the D3 receptor is always evident. The highest D3 affinity may be achieved if benzo[b]thiophene or indol is used as the heteroarene component. For example, compounds of the examples 1, 2, 10 to 13 and 19 to 22 have excellent Ki values between 0.23 and 057 nM.
The substitution pattern of the arylpiperazine component primarily influences : the degree of selectivity of the D3 affinity vis-a-vis the other receptor subtypes. With selection coefficients of more than 1000, the 2,3- dichlorophenyl-substituted compounds (examples 2, 6, and 10) display a D3 selectivity hitherto not described with concomitant subnanomolar affinity. It is interesting that the ferrocenyl derivatives of the examples 16 and 17 are characterised by a high D4 affinity, example 17 with Ki values of 0.47 nM for : : the D3 receptor and 0.63 nM for the D4 receptor showing an extraordinary receptor binding profile.
Tests to determine the intrinsic activity of the compounds of the examples were carried out in a mitogenesis assay as described in literature (Hiibner, H. et al. J. Med. Chem. 2000, 43, 4563-4569; Liber, S. Bioorg. Med. Chem. Lett. 2002, 12.17, 2377-2380). A partial agonistic activity of 49 % of the maximum receptor stimulation is illustrative for the compound of example 1, which may be triggered by the full agonist Quinpirol as the reference compound. Curve calculations of this concentration-activity test resulted in an ECs value of 0.38 nM.
Table 1: Binding data and selectivity patterns of the compounds of the formulae (I) to (IV) for the dopamine receptors pD1, hD2long, hD2short, hD3 - and hD4.4 — ____ _ D3selectivity
Ki-values in [nM]? —_—
Compound — ~~ D2long/D3 D2short/D3 D4.4/D3
D1 D2long D2short D3 D44 -
Example1 670 87 52 023 15 380 230 65
Example 2 8800 3300 2600 0,5 340 6600 5200 680
Example3 1100 110 84 L130 100 76 27
Example 4 2900 320 80 1,2 93 270 67 78
Example 5 590 96 61 0,69 17 140 88 25
- @ 35 PCT/EP2003/007060 ®
Example 6 2100 10000 4800 34 3100 2900 1400 910
Example 7 1400 130 89 42 57 31 21 14
Example 8 380 63 39 0,72 35 88 54 49
Example 9 1400 91 48 0,55 150 170 87 270
Example 1100 3100 1600 0,56 1700 5500 2900 3000 ~ Example 920 140 99 0,57 24 250 180 44
Example 390 110 44 0,24 16 460 180 67
Example 460 160 100 0,25 40 640 400 160
Example 4200 2300 770 0,73 600 3200 1100 820
Example 1700 340 110 0,35 630 970 310 1800
Example 1500 110 78 6,5 040 17 12 0,061
Example 630 31 19 0,47 0,63 66 40 1,3 EB : Example 430 68 39 0,46 45 150 85 98
Example 1700 410 310 0,25 650 1600 1200 2600
Example 1100 210 130 0,33 37 640 390 110
Example 1700 180 60 0,26 72 690 230 280
Example 550 49 30 0,26 58 190 120 220
Example 4700 1700 970 3,2 1700 1500 300 530
Example 1200 200 160 0,70 40 290 230 57
Example 1700 140 27 091 210 150 30 230 ? Average values from 2 - 9 individual experiments carried out as triplicates
The investigation of the affinities to the serotonin receptor subtypes 5-HT1A and 5-HT2 and to the adrenergic receptor al is described in table 2.
Irrespective of the partial structures of the derivatives, a preferred binding to the 5-HT1A subtype when compared with 5-HT2 can be observed. With measured Ki values of 8 to 19 nM, the compounds of the examples 1, 3, 7, 8 : and 16 are characterised by a high affinity to the al receptor.
Considerations concerning structure/activity show a clear dependence on the substitution pattern of the aryl piperazine partial structure for the binding to these receptors. As with the dopamine receptors, the binding to the 5-HT and to the al receptor is clearly diminished in the derivatives with a 2,3- dichlorophenyl radical which results in an extension of the selectivity spectrum vis-a-vis the D3 receptor affinity of these compounds.
@ 36 PCT/EP2003/007060
Lg Table 2: Binding data of substances of the formulae (I) to (IV) for the serotonin receptors pS-HTIA, p5-HT2 and for the adrenergic receptor subtype pal
Ki values in [nM]?
Compounds SHTIA 5_HT2® ol® old : Example 1 41 350 15 6,4
Example 2 360 2000 --- 370
Example 3 17 - 660 14 33
Example 4 480 11000 --- 160
Example5 68 140 -- 5,3 © Example 6 2500 © 540 --- 1300
Example 7 37 390 8,2 11
Example 8 69 420 15 3,5
Example 9 130 730 --- 100
Example 10 610 1700 --- 220
Example 11 8&3 440 24 5,9
Example 12 440 280 --- 6,4
Example 13 47 220 --- 4,3
Example 14 1600 690 --- 500
Example 15 390 320 --- 2000
Example 16 0,60 500 19 30
Example 17 27 : 250 --- 73
Example 18 54 580 -- 2,9
Example 19 190 280 -—- 230
Example 20 71 660 ev 8,3
Example 21 110 290 --- 45
Example 22 180 760 --- 2,5
Example 23 430 14000 --- 320
Example 24 32 420 11 7,3
Example 25 190 20 -. 220 * Average values from 2 to 6 individual experiments carried out with triplicates ® Kj value in case of simultaneous incubation with 10 uM of Prazosin © Ki value derived from the highly affine binding site in case of labelling with [*H]K etanserin 4 Ki value from the competitive experiment with the al selective radio ligand [*H]Prazosin
Claims (3)
1. A compound of the general formula (I) Ri 4 roo 5 LO HOE Ny - NO \ ye 0 6 Pa X H a \_/ \ 2 Rs : 7 wherein: - n=1-4and - R =hydrogen, alkyl or halogen and (a X=SorO: (1) when Rj is hydroxy, alkyloxy, alkenyl, alkinyl, aryl, : acyl, alkoxycarbonyl or cyano, each of Ry and Rj are independently selected from hydrogen, hydroxy, alkyloxy, alkyl, alkenyl, alkinyl, aryl, halogen, trifluoromethyl, acyl, alkoxycarbonyl and cyano, (ii) when Rj is hydrogen, alkyl, halogen or trifluoromethyl, Ry is selected from hydroxy, alkenyl, alkinyl, aryl, acyl, alkoxycarbonyl and cyano and Rj is selected from hydrogen, hydroxy, alkyloxy, alkyl, alkenyl, alkinyl, aryl, halogen, trifluoromethyl, acyl, alkoxycarbonyl and cyano, or (b) X=NH: R] is selected from hydrogen, hydroxy, alkyl, alkyloxy, alkenyl, alkinyl, aryl, trifluoromethyl, acyl, alkoxycarbonyl, halogen and cyano and each of Ry and Rj3 are selected independently from hydrogen, hydroxy, alkyloxy, alkyl, alkenyl, alkinyl, aryl,
38 PCT/EP2003/007060 halogen, trifluoromethyl, acyl, alkoxycarbonyl and cyano, with the proviso that the compound is not N-4-(4-(2- methoxyphenyl)piperazine-1-yl)butyl-2-indolylcarbamide, or (c) X=Te Rj is selected from hydrogen, hydroxy, alkyl, alkyloxy, alkenyl, alkinyl, aryl, halogen, trifluoromethyl, acyl, alkoxycarbonyl and cyano and each of Ry and Rj are selected independently from hydrogen, hydroxy, alkyloxy, alkyl, alkenyl, alkinyl, aryl, halogen, trifluoromethyl, acyl, alkoxycarbonyl and cyano. : wherein the groups alkyl, alkenyl, alkinyl and aryl may optionally be - substituted independently of one another, and pharmaceutically acceptable salts of this compound.
2. A compound according to claim 1 wherein - n=1-4 and _ X = Te, when R = hydrogen, alkyl or halogen and R7 is substituted by the radicals hydrogen, hydroxy, alkyl, alkyloxy, alkenyl, alkinyl, aryl, halogen, trifluoromethyl, acyl, alkoxycarbonyl or cyano and R) and R3 are substituted individually or jointly by the radicals hydrogen, hydroxy, alkyloxy, alkyl, alkenyl, alkinyl, aryl, halogen, - trifluoromethyl, acyl, alkoxycarbonyl or cyano, or _ X=S or O, when R = hydrogen, alkyl or halogen and Ry is substituted by the radicals hydroxy, alkyloxy, alkenyl, alkinyl, aryl, acyl, : alkoxycarbonyl or cyano and Rp and Rj are substituted individually or jointly by the radicals hydrogen, hydroxy, alkyloxy, alkyl, alkenyl, alkinyl, aryl, halogen, trifluoromethyl, acyl, alkoxycarbonyl or cyano, or - X =S or 0, when R = hydrogen, alkyl or halogen and R; is substituted : by the radicals hydrogen, alkyl, halogen or trifluoromethyl and R) and
39 PCT/EP2003/007060
Rj are substituted individually or jointly by the radicals hydroxy,
alkenyl, alkinyl, aryl, acyl, alkoxycarbony! or cyano,
or - X =NH, when R = hydrogen, alkyl or halogen and R is substituted by the radicals hydroxy, alkyl, alkyloxy, alkenyl, alkinyl, aryl, trifluoromethyl, acyl, alkoxycarbonyl or cyano, it being required that alkyl and alkyloxy contain at least two carbon atoms, and Rp and Rj BN are substituted individually or jointly by the radicals hydrogen, hydroxy, alkyloxy, alkyl, alkenyl, alkinyl, aryl, halogen, trifluoromethyl, acyl, alkoxycarbonyl or cyano and alkyloxy comprises at least two carbon atoms.
3 A compound according to claim’ having the general formula (Ia) or
(Ib): Ri 4 joo 5 SA OE ; NO N D4 (Ia) NF 5 H n \_/ \ 7 Rs
7 2-3 Ry 4 R o 6 5 5rN ON \ /N\ = Ro J : fp wherein: - n=1-4, - R =hydrogen, C;-C¢-alkyl or halogen,
: - when Rj is hydroxy, C;-Cs-alkyloxy, C,-Cg-alkenyl, C,-Cg-alkinyl, phenyl that may optionally be substituted with a methoxy group or halogen, C;-Cg-acyl, C,-Cg-alkoxy carbonyl or cyano, each of Ry and R3 are independently selected from hydrogen, hydroxy, C;-Cs- alkyloxy, C;-Cg-alkyl, C;-Cg-alkenyl, C,-Ce-alkinyl, phenyl that may optionally be substituted with a methoxy group or halogen, halogen, trifluoromethyl, C;-C¢-acyl, C,-Cg-alkoxycarbonyl and cyano,
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10230062 | 2002-07-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200410292B true ZA200410292B (en) | 2005-10-06 |
Family
ID=30774917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200410292A ZA200410292B (en) | 2002-07-04 | 2004-12-21 | Utilization of heteroarene carboxamide as dopamine-D3 ligands for the treatment of CNS diseases. |
Country Status (6)
Country | Link |
---|---|
EP (2) | EP1749529A1 (en) |
DE (1) | DE10232020A1 (en) |
PT (1) | PT1519726E (en) |
SI (1) | SI1519726T1 (en) |
UA (1) | UA81630C2 (en) |
ZA (1) | ZA200410292B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102264733B (en) | 2008-10-10 | 2014-07-30 | 中国人民解放军军事医学科学院毒物药物研究所 | Novel dopamine d3 receptor ligands, the preparation and use thereof |
US9227944B2 (en) | 2008-10-10 | 2016-01-05 | Institute Of Pharmacology And Toxicology Academy Of Military Science P.L.A. China | Dopamine D3 receptor ligands and preparation and medical uses of the same |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3734915A (en) | 1970-02-02 | 1973-05-22 | American Cyanamid Co | N-(-(4-phenyl-1-piperazinyl)alkyl)benzo(b)thiophene or benzofuran-2-carboxamides |
US3646047A (en) | 1970-02-02 | 1972-02-29 | American Cyanamid Co | Certain benzo(b)thiophene-2-carboxamide derivatives |
CA1340113C (en) | 1988-05-24 | 1998-11-03 | Magid A. Abou-Gharbia | Aryl-and heteroaryl piperazinyl carboxamides having central nervous system activity |
ES2027898A6 (en) * | 1991-01-24 | 1992-06-16 | Espanola Prod Quimicos | 2-Methoxyphenylpiperazine derivatives. |
FR2679451B1 (en) | 1991-07-22 | 1994-09-09 | Prographarm Laboratoires | MULTIPARTICLE TABLET WITH RAPID DELIVERY. |
DE4425146A1 (en) * | 1994-07-15 | 1996-01-18 | Basf Ag | Use of heterocyclic compounds |
FR2742149B1 (en) | 1995-12-11 | 1998-02-13 | Inst Nat Sante Rech Med | NOVEL 2-NAPHTAMIDE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS |
FR2785538B1 (en) | 1998-11-06 | 2004-04-09 | Prographarm Laboratoires | PERFECTED QUICK DELIVERY TABLET |
HUP0103987A3 (en) * | 2001-09-28 | 2004-11-29 | Richter Gedeon Vegyeszet | Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates |
-
2002
- 2002-07-10 DE DE10232020A patent/DE10232020A1/en not_active Withdrawn
-
2003
- 2003-07-02 UA UA20041210938A patent/UA81630C2/en unknown
- 2003-07-02 EP EP06019977A patent/EP1749529A1/en not_active Withdrawn
- 2003-07-02 SI SI200330730T patent/SI1519726T1/en unknown
- 2003-07-02 EP EP06020274A patent/EP1733727A1/en not_active Withdrawn
- 2003-07-02 PT PT03762588T patent/PT1519726E/en unknown
-
2004
- 2004-12-21 ZA ZA200410292A patent/ZA200410292B/en unknown
Also Published As
Publication number | Publication date |
---|---|
SI1519726T1 (en) | 2007-06-30 |
EP1733727A1 (en) | 2006-12-20 |
UA81630C2 (en) | 2008-01-25 |
PT1519726E (en) | 2007-04-30 |
DE10232020A1 (en) | 2004-02-26 |
EP1749529A1 (en) | 2007-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR0179661B1 (en) | N-phenylalkyl substituted alpha-amindocarboxamide derivatives and process for their preparation | |
EP0557171B1 (en) | Azaindoles, process for their preparation and medicines containing them | |
RU2544856C2 (en) | NEW 2,3,4,5-TETRAHYDRO-1-PYRIDO[4,3-b]INDOLE DERIVATIVES AND METHODS FOR USING THEM | |
AU2006224853B2 (en) | Trifluoromethylbenzamide derivatives and therapeutic uses thereof | |
US20050197343A1 (en) | Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases | |
JPH06107649A (en) | Benzanilide derivative | |
WO1996002525A1 (en) | Novel aryl piperazine-derived piperazide derivatives, methods for their preparation, their use as drugs and pharmaceutical compositions comprising same | |
EP0506532A1 (en) | Indole derivatives, process for their preparation and medicaments containing them | |
CA2715282A1 (en) | Indole compounds and methods of use thereof | |
US8501762B2 (en) | Tetrahydroprotoberberine compounds, the synthetic method and the use thereof | |
FR2493845A1 (en) | SUBSTITUTED BENZOFURAN-2 DERIVATIVES USEFUL AS MEDICAMENTS AND METHODS OF PREPARATION | |
US5332759A (en) | Naphthalene amides and sulphonamides, processes for their preparation and pharmaceutical compositions containing them | |
JPH11147871A (en) | New piperazine compound | |
EP0594813A1 (en) | Novel amidoalkyl- and imidoalkyl-piperazines | |
AU704261B2 (en) | Novel tricyclic amides, processes for their preparation and the pharmaceutical compositions which contain them | |
NZ286340A (en) | Amides of 2-(4-indolyl piperazia-1-yl)-1-ph-enyl (and bemzyl)ethyl amine derivatives with various (cyclo) alkane carboxylic acids; pharmaceutical compositions | |
ZA200410292B (en) | Utilization of heteroarene carboxamide as dopamine-D3 ligands for the treatment of CNS diseases. | |
PT98372A (en) | PREPARATION PROCEDURE OF BENZIDRYL DERIVATIVES WITH INHIBITOR PROPERTIES OF CALMODULIN AND PHARMACEUTICAL COMPOSITIONS | |
CZ325196A3 (en) | Derivatives of hydroximic acid, pharmaceutical compositions containing thereof, process of their preparation and intermediates used in the preparation process | |
CZ289080B6 (en) | N-substituted azabicycloheptane derivative, process of its preparation and use | |
NZ537477A (en) | Use of N-[(4-phenyl-1-piperazinyl)alkyl]-substituted heteroarene carboxamide in the treatment of CNS diseases | |
JP3091233B2 (en) | New N-aminoalkyl-1-biphenylenyl-2-carboxamides, new dopamine receptor / subtype specific ligands | |
KR100503518B1 (en) | Process for the preparation of 2-(4-alkyl-1-piperazinyl)-benzaldehyde and -benzylidenyl compounds | |
JPH0222252A (en) | 5-hydroxytriptamine-1a-receptor bonding compound | |
US5510374A (en) | 3-aminochroman compounds |